<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Disitamab Vedotin (RC48) - Complete Investment Analysis | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
        <script src="https://unpkg.com/lucide@latest"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
            background: #f8f9fa;
            color: #333;
            font-size: 14px;
            line-height: 1.5;
        }

        .nav-bar {
            background: white;
            height: 56px;
            display: flex;
            align-items: center;
            padding: 0 24px;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }

        .container {
            margin-top: 56px;
            padding: 32px 24px;
            max-width: 1400px;
            margin-left: auto;
            margin-right: auto;
        }

        .tab-container {
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.06);
            overflow: hidden;
            margin-top: 24px;
        }

        .tabs {
            display: flex;
            border-bottom: 2px solid #e3f2f0;
            overflow-x: auto;
            background: #fafffe;
        }

        .tab-btn {
            padding: 14px 20px;
            border: none;
            background: none;
            color: #6c757d;
            font-size: 13px;
            font-weight: 600;
            cursor: pointer;
            white-space: nowrap;
            border-bottom: 3px solid transparent;
            transition: all 0.2s;
        }

        .tab-btn:hover {
            color: #0a6b5e;
            background: #f0f7f6;
        }

        .tab-btn.active {
            color: #0a6b5e;
            border-bottom-color: #0a6b5e;
            background: white;
        }

        .tab-content {
            padding: 24px;
            display: none;
        }

        .tab-content.active {
            display: block;
        }

        .section-title {
            font-size: 20px;
            font-weight: 600;
            color: #0a6b5e;
            margin-bottom: 16px;
        }

        .subsection-title {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-top: 20px;
            margin-bottom: 12px;
        }

        .data-card {
            background: #f8fffe;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
            margin-bottom: 16px;
        }

        .detail-text {
            color: #424242;
            line-height: 1.6;
            margin-bottom: 12px;
        }

        .metric-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(250px, 1fr));
            gap: 16px;
            margin-top: 16px;
        }

        .metric-card {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
        }

        .metric-label {
            font-size: 12px;
            color: #6c757d;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 8px;
        }

        .metric-value {
            font-size: 24px;
            font-weight: 600;
            color: #0a6b5e;
        }

        .metric-detail {
            font-size: 12px;
            color: #6c757d;
            margin-top: 4px;
        }

        .expandable-section {
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            margin-bottom: 12px;
            overflow: hidden;
        }

        .expandable-header {
            background: #f0f7f6;
            padding: 12px 16px;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            font-weight: 600;
            color: #0a6b5e;
            transition: background 0.2s;
        }

        .expandable-header:hover {
            background: #e6f3f1;
        }

        .expandable-content {
            padding: 16px;
            display: none;
            background: white;
        }

        .expandable-content.active {
            display: block;
        }

        .timeline-container {
            position: relative;
            padding-left: 40px;
            margin: 20px 0;
        }

        .timeline-line {
            position: absolute;
            left: 12px;
            top: 24px;
            bottom: 24px;
            width: 2px;
            background: #e3f2f0;
        }

        .timeline-item {
            position: relative;
            margin-bottom: 24px;
        }

        .timeline-dot {
            position: absolute;
            left: -32px;
            top: 4px;
            width: 12px;
            height: 12px;
            background: #0a6b5e;
            border: 3px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }

        .timeline-date {
            font-size: 12px;
            color: #6c757d;
            font-weight: 600;
            margin-bottom: 4px;
        }

        .timeline-content {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 12px;
        }

        .trial-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 16px;
        }

        .trial-table th {
            background: #f0f7f6;
            padding: 12px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: #0a6b5e;
            border-bottom: 2px solid #e3f2f0;
        }

        .trial-table td {
            padding: 12px;
            border-bottom: 1px solid #f0f7f6;
            font-size: 13px;
            vertical-align: top;
        }

        .status-badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 6px;
            font-size: 11px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .status-active { 
            background: #d4f4ec;
            color: #0a6b5e;
        }

        .status-completed { 
            background: #e3f2f0;
            color: #0a6b5e;
        }

        .status-recruiting { 
            background: #cfe2ff;
            color: #084298;
        }

        .status-approved {
            background: #28a745;
            color: white;
        }

        .link-btn {
            color: #0a6b5e;
            text-decoration: none;
            font-size: 12px;
            font-weight: 600;
            display: inline-flex;
            align-items: center;
            gap: 4px;
            padding: 4px 8px;
            border-radius: 4px;
            transition: all 0.2s;
        }

        .link-btn:hover {
            background: #f0f7f6;
        }

        .ae-table {
            width: 100%;
            margin-top: 16px;
        }

        .ae-table th {
            background: #fff3cd;
            padding: 10px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: #856404;
        }

        .ae-table td {
            padding: 10px;
            border-bottom: 1px solid #fff3cd;
            font-size: 13px;
        }

        .reference-list {
            font-size: 11px;
            color: #6c757d;
            margin-top: 8px;
            padding-top: 8px;
            border-top: 1px solid #e3f2f0;
        }

        .chart-container {
            position: relative;
            height: 300px;
            margin: 20px 0;
        }

        .regulatory-flow {
            display: flex;
            align-items: center;
            gap: 20px;
            margin: 20px 0;
            overflow-x: auto;
            padding: 20px 0;
        }

        .flow-node {
            background: white;
            border: 2px solid #0a6b5e;
            border-radius: 8px;
            padding: 16px;
            min-width: 200px;
            text-align: center;
            position: relative;
        }

        .flow-node.completed {
            background: #d4f4ec;
        }

        .flow-node.active {
            background: #cfe2ff;
            border-color: #084298;
        }

        .flow-arrow {
            position: absolute;
            right: -25px;
            top: 50%;
            transform: translateY(-50%);
            color: #0a6b5e;
            font-size: 20px;
        }

        .highlight-box {
            background: linear-gradient(135deg, #f0f7f6 0%, #e6f3f1 100%);
            border-left: 4px solid #0a6b5e;
            padding: 16px;
            margin: 16px 0;
            border-radius: 0 8px 8px 0;
        }

        .risk-item {
            display: flex;
            align-items: flex-start;
            margin-bottom: 12px;
        }

        .risk-indicator {
            width: 8px;
            height: 8px;
            border-radius: 50%;
            margin-right: 12px;
            margin-top: 6px;
            flex-shrink: 0;
        }

        .risk-high { background: #dc3545; }
        .risk-medium { background: #ffc107; }
        .risk-low { background: #28a745; }

            /* Custom animations and effects */
        @keyframes float {
            0%, 100% { transform: translateY(0px); }
            50% { transform: translateY(-3px); }
        }
        
        @keyframes pulse-glow {
            0%, 100% { opacity: 0.3; }
            50% { opacity: 0.6; }
        }
        
        .nav-bar {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
            border-bottom: 1px solid rgba(229, 231, 235, 0.6);
            box-shadow: 0 4px 20px -2px rgba(0, 0, 0, 0.05);
            position: relative;
            overflow: hidden;
        }
        
        /* Animated gradient background */
        .nav-bar::before {
            content: '';
            position: absolute;
            top: 0;
            left: -100%;
            width: 200%;
            height: 2px;
            background: linear-gradient(90deg, 
                transparent,
                #10b981,
                #06b6d4,
                #8b5cf6,
                transparent
            );
            animation: shimmer 3s infinite;
        }
        
        @keyframes shimmer {
            0% { left: -100%; }
            100% { left: 100%; }
        }
        
        .nav-tab {
            position: relative;
            padding: 0.5rem 1rem;
            color: #6b7280;
            font-weight: 500;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            border-radius: 0.625rem;
            display: flex;
            align-items: center;
            gap: 0.375rem;
            font-size: 0.875rem;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            color: #1f2937;
            background: linear-gradient(135deg, 
                rgba(16, 185, 129, 0.05),
                rgba(6, 182, 212, 0.05)
            );
            transform: translateY(-1px);
        }
        
        .nav-tab.active {
            color: #fff;
            background: linear-gradient(135deg, #10b981, #06b6d4);
            box-shadow: 0 4px 15px -3px rgba(16, 185, 129, 0.3);
        }
        
        .nav-tab svg {
            transition: all 0.3s ease;
        }
        
        .nav-tab:hover svg {
            transform: scale(1.1) rotate(5deg);
        }
        
        .nav-tab.active svg {
            filter: brightness(1.2);
            animation: float 3s ease-in-out infinite;
        }
        
        .logo-container {
            animation: float 4s ease-in-out infinite;
        }
        
        .glow-effect {
            animation: pulse-glow 2s ease-in-out infinite;
        }
        
        /* Gradient text animation on hover */
        .brand-text {
            background-size: 200% 200%;
            transition: all 0.3s ease;
        }
        
        .brand-container:hover .brand-text {
            background-position: 100% 0;
            filter: brightness(1.1);
        }
        
        /* Mobile responsive */
        @media (max-width: 1024px) {
            .nav-tabs {
                gap: 0.25rem;
            }
            
            .nav-tab {
                padding: 0.4rem 0.75rem;
                font-size: 0.8rem;
            }
            
            .nav-tab svg {
                width: 0.875rem;
                height: 0.875rem;
            }
            
            .brand-text {
                font-size: 1rem;
            }
        }
        
        @media (max-width: 768px) {
            .nav-bar {
                padding: 0.75rem 1rem;
            }
            
            .nav-tabs {
                display: none; /* Hide on mobile to prevent squashing */
            }
            
            .nav-tab {
                width: 100%;
                justify-content: center;
            }
        }
/* Replace the navigation styles (lines ~445-609) with this updated version */

/* Custom animations and effects */
@keyframes float {
    0%, 100% { transform: translateY(0px); }
    50% { transform: translateY(-3px); }
}

@keyframes pulse-glow {
    0%, 100% { opacity: 0.3; }
    50% { opacity: 0.6; }
}

@keyframes shimmer {
    0% { left: -100%; }
    100% { left: 100%; }
}

.nav-bar {
    background: rgba(255, 255, 255, 0.95);
    backdrop-filter: blur(20px);
    -webkit-backdrop-filter: blur(20px);
    border-bottom: 1px solid rgba(229, 231, 235, 0.6);
    box-shadow: 0 4px 20px -2px rgba(0, 0, 0, 0.05);
    position: relative;
    overflow: hidden;
    height: auto;
    min-height: 80px;
    display: flex;
    align-items: center;
}

/* Animated gradient background line */
.nav-bar::before {
    content: '';
    position: absolute;
    top: 0;
    left: -100%;
    width: 200%;
    height: 2px;
    background: linear-gradient(90deg, 
        transparent,
        #0a6b5e,
        #085a4f,
        #0a6b5e,
        transparent
    );
    animation: shimmer 3s infinite;
}

.nav-tab {
    position: relative;
    padding: 0.5rem 1rem;
    color: #6b7280;
    font-weight: 500;
    transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
    border-radius: 0.625rem;
    display: flex;
    align-items: center;
    gap: 0.375rem;
    font-size: 0.875rem;
    white-space: nowrap;
    text-decoration: none;
}

.nav-tab:hover {
    color: #0a6b5e;
    background: linear-gradient(135deg, 
        rgba(10, 107, 94, 0.08),
        rgba(8, 90, 79, 0.05)
    );
    transform: translateY(-1px);
}

.nav-tab.active {
    color: #fff;
    background: linear-gradient(135deg, #0a6b5e, #085a4f);
    box-shadow: 0 4px 15px -3px rgba(10, 107, 94, 0.4);
}

.nav-tab svg {
    transition: all 0.3s ease;
}

.nav-tab:hover svg {
    transform: scale(1.1) rotate(5deg);
}

.nav-tab.active svg {
    filter: brightness(1.2);
    animation: float 3s ease-in-out infinite;
}

.logo-container {
    animation: float 4s ease-in-out infinite;
}

.glow-effect {
    animation: pulse-glow 2s ease-in-out infinite;
}

/* Gradient text animation on hover */
.brand-text {
    background-size: 200% 200%;
    transition: all 0.3s ease;
}

.brand-container:hover .brand-text {
    background-position: 100% 0;
    filter: brightness(1.1);
}

/* Mobile responsive */
@media (max-width: 1024px) {
    .nav-tabs {
        gap: 0.25rem;
    }
    
    .nav-tab {
        padding: 0.4rem 0.75rem;
        font-size: 0.8rem;
    }
    
    .nav-tab svg {
        width: 0.875rem;
        height: 0.875rem;
    }
    
    .brand-text {
        font-size: 1rem;
    }
}

@media (max-width: 768px) {
    .nav-bar {
        padding: 0.75rem 1rem;
    }
    
    .nav-tabs {
        display: none;
    }
    
    .nav-tab {
        width: 100%;
        justify-content: center;
    }
}
    </style>
</head>
<body>
    <!-- Navigation -->
       <nav class="nav-bar" style="height: auto; min-height: 80px;">
        <div class="w-full px-8 py-4">
            <div class="flex items-center justify-between gap-8">
                <!-- Logo and Brand - Fixed width to prevent squashing -->
                <div class="brand-container flex items-center gap-4 cursor-pointer group flex-shrink-0" onclick="location.href='/blackstone.html'">
                    <div class="logo-container relative">
                        <!-- Using your existing logo -->
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-12 w-12 object-contain relative z-10 transition-transform duration-300 group-hover:scale-110">
                        
                        <!-- Enhanced glow effect with multiple layers -->
                        <div class="absolute inset-0 bg-gradient-to-r from-emerald-400 via-cyan-400 to-purple-400 opacity-30 blur-xl rounded-full glow-effect"></div>
                        <div class="absolute inset-0 bg-gradient-to-r from-emerald-300 to-cyan-300 opacity-20 blur-2xl rounded-full scale-150"></div>
                    </div>
                    
                    <div class="flex flex-col">
                        <span class="brand-text text-xl font-bold bg-gradient-to-r from-emerald-600 via-blue-600 to-purple-600 bg-clip-text text-transparent whitespace-nowrap">
                            Leaf Intelligence
                        </span>
                        <div class="flex items-center gap-2">
                            <div class="flex items-center gap-1">
                                <div class="w-1.5 h-1.5 bg-emerald-500 rounded-full animate-pulse"></div>
                                <span class="text-xs text-gray-600 font-medium">AI Research Platform</span>
                            </div>
                            <span class="text-xs bg-gradient-to-r from-emerald-500 to-cyan-500 text-white px-2 py-0.5 rounded-full font-semibold">BETA</span>
                        </div>
                    </div>
                </div>
                
                <!-- Navigation Tabs - Center aligned with proper spacing -->
                <div class="nav-tabs flex items-center gap-2 flex-grow justify-center">
                    <a href="/blackstone.html" class="nav-tab active">
                        <i data-lucide="building-2" class="w-4 h-4"></i>
                        <span>Companies</span>
                    </a>
                    <a href="/competitive.html" class="nav-tab">
                       <i data-lucide="beaker" class="w-4 h-4"></i>
                        <span>Pharma Intelligence</span>
                    </a>
                    <a href="/comparison.html" class="nav-tab">
                        <i data-lucide="git-compare" class="w-4 h-4"></i>
                        <span>Side-By-Side</span>
                    </a>
                </div>
                
                <!-- Right side actions - Fixed width -->
                <div class="flex items-center gap-2 flex-shrink-0">
                    <button class="p-2 hover:bg-gray-100 rounded-lg transition-colors">
                        <i data-lucide="search" class="w-4 h-4 text-gray-600"></i>
                    </button>
                    <button class="p-2 hover:bg-gray-100 rounded-lg transition-colors relative">
                        <i data-lucide="bell" class="w-4 h-4 text-gray-600"></i>
                        <span class="absolute top-1 right-1 w-1.5 h-1.5 bg-red-500 rounded-full"></span>
                    </button>
                    <div class="w-px h-6 bg-gray-200"></div>
                    <!-- <button class="flex items-center gap-2 px-3 py-1.5 bg-gradient-to-r from-emerald-500 to-cyan-500 text-white rounded-lg font-medium text-sm hover:shadow-lg transition-all hover:scale-105">
                        <i data-lucide="sparkles" class="w-3.5 h-3.5"></i>
                        <span>Upgrade</span>
                    </button> -->
                </div>
            </div>
        </div>
    </nav>

    <!-- Main Content -->
    <div class="container">
        <!-- Header -->
        <div class="bg-white rounded-lg p-6 shadow-sm mb-6">
            <div class="flex justify-between items-start">
                <div>
                    <h1 class="text-3xl font-bold text-gray-900">Disitamab Vedotin (RC48/Aidixi®)</h1>
                    <p class="text-lg text-gray-600 mt-2">HER2-Targeted Antibody-Drug Conjugate with MMAE Payload</p>
                    <div class="flex gap-4 mt-4">
                        <span class="status-badge status-approved">Approved China</span>
                        <span class="text-sm text-gray-600">RemeGen / Pfizer-Seagen Partnership</span>
                        <span class="text-sm text-gray-600">Target: HER2+ & HER2-low Breast Cancer</span>
                    </div>
                </div>
                <div class="text-right">
                    <div class="text-sm text-gray-500">China Regulatory Status</div>
                    <div class="text-2xl font-bold text-green-600">NMPA Approved</div>
                    <div class="text-sm text-gray-500">3 Indications • NRDL Listed</div>
                    <div class="text-sm text-gray-500">Global Development: Phase 2-3</div>
                </div>
            </div>
        </div>

        <!-- Tab Container -->
        <div class="tab-container">
            <div class="tabs">
                <button class="tab-btn active" onclick="showTab('overview')">Overview</button>
                <button class="tab-btn" onclick="showTab('clinical')">Clinical & Regulatory</button>
                <button class="tab-btn" onclick="showTab('scientific')">Scientific & IP</button>
                <button class="tab-btn" onclick="showTab('commercial')">Commercial & Market</button>
                <button class="tab-btn" onclick="showTab('financial')">Financial & Strategic</button>
                <button class="tab-btn" onclick="showTab('operational')">Operational & Legal</button>
                <button class="tab-btn" onclick="showTab('management')">Management & Team</button>
                <button class="tab-btn" onclick="showTab('safety')">Safety & Toxicology</button>
                <button class="tab-btn" onclick="showTab('trials')">Complete Trial Analysis</button>
            </div>




<!-- Overview Tab Content (add this with other tab contents) -->
<div id="overview" class="tab-content active">
    <div class="section-title">Executive Overview: Complete Diligence Assessment</div>
    
    <!-- Executive Summary -->
    <div class="highlight-box">
        <h3 class="text-xl font-bold mb-4 text-gray-900">Investment Committee Executive Brief</h3>
        <p class="detail-text">
            Disitamab vedotin (RC48, Aidixi®) represents a HER2-targeted antibody-drug conjugate with moderate probability of global regulatory success (40-50%) for HER2-positive metastatic breast cancer with liver metastases, based on its narrow Chinese approval and the need for new trials against current standards like trastuzumab deruxtecan. The asset demonstrates a favorable safety profile with low ILD risk that could differentiate it in later lines, positioning it for third-line or later therapy globally, similar to precedents like trastuzumab deruxtecan in post-trastuzumab settings, with potential for a biomarker-defined label in HER2-low populations if additional data support broader use.
        </p>
    </div>

    <!-- 1. Regulatory Guidance & Interactions -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>1. Regulatory Guidance & Interactions</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="data-card">
                <h4 class="font-semibold mb-2">Complete Regulatory Interaction History</h4>
                <p class="detail-text">
                    Regulatory interactions for Disitamab vedotin have emphasized targeted indications and robust endpoints, with NMPA granting Breakthrough Therapy Designation and priority review leading to its May 2025 approval based on RC48-C006 (NCT03500380), where lapatinib + capecitabine was selected as control per Chinese guidelines for later-line HER2-positive mBC.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">NMPA Interactions</div>
                    <div class="metric-value">BTD + Priority</div>
                    <div class="metric-detail">Approved May 2025</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">FDA Status</div>
                    <div class="metric-value">BTD (UC)</div>
                    <div class="metric-detail">2020 designation</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">EMA Interactions</div>
                    <div class="metric-value">PIP Filed</div>
                    <div class="metric-detail">2025 pediatric plan</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Control Arm</div>
                    <div class="metric-value">Regulator-Guided</div>
                    <div class="metric-detail">Lapatinib+cape per NMPA</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Regulatory Guidance Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>Meeting History:</strong> No specific pre-IND or End-of-Phase 2 meeting dates are public, but FDA's 2020 Breakthrough Therapy for urothelial cancer implies similar consultations for breast, with potential SPA for global Phase 3</li>
                    <li>• <strong>Endpoint Hierarchy:</strong> Regulators advised PFS as primary (met with HR 0.56, P=0.0143) and OS as key secondary (immature but trending HR 0.56), plus safety monitoring for neuropathy</li>
                    <li>• <strong>Sponsor Compliance:</strong> Sponsors followed closely, without noted divergences, enabling conditional approval in China</li>
                    <li>• <strong>Label Implications:</strong> For EMA/FDA, implications include accelerated pathways for unmet niches like post-T-DXd failure, likely monotherapy in 3L+, with full approval requiring OS confirmation</li>
                    <li>• <strong>Combo Strategy:</strong> Combo-only if synergies with PD-1 inhibitors prove essential in ongoing trials</li>
                    <li>• <strong>Updates:</strong> Updates post-2024 SABCS interim and competitor ILD concerns may refine labels toward safer alternatives</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003443-pip02-23" target="_blank" class="link-btn">EMA PIP</a> | 
                <a href="https://www.oncozine.com/disitamab-vedotin-receives-fda-breakthrough-therapy-designation-for-treatment-of-urothelial-cancer/" target="_blank" class="link-btn">FDA BTD</a>
            </div>
        </div>
    </div>

    <!-- 2. Standard of Care Dossier -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>2. Standard of Care (SoC) Dossier</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Global SoC Context</h4>
                <p class="detail-text">
                    The standard of care for HER2-positive metastatic breast cancer emphasizes dual HER2 blockade plus chemotherapy in the first line across the US and EU, while China and Japan may incorporate more oral regimens due to access; weaknesses include rapid resistance and variable survival benefits in visceral disease. The SoC for HER2-positive mBC is HER2-directed therapy escalating by line, with global variations in access and preferences.
                </p>
            </div>

            <table class="trial-table mt-4">
                <thead>
                    <tr>
                        <th>Line of Therapy</th>
                        <th>US/EU Regimens</th>
                        <th>Efficacy (ORR/PFS/OS)</th>
                        <th>Safety</th>
                        <th>Weaknesses</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>1L</strong></td>
                        <td>THP (Approved)</td>
                        <td>ORR 80%, PFS 18-24mo, OS 57mo</td>
                        <td>Neutropenia 50%, neuropathy 20%</td>
                        <td>Resistance, no mutant OS</td>
                    </tr>
                    <tr>
                        <td><strong>2L</strong></td>
                        <td>T-DXd (Approved)</td>
                        <td>ORR 79%, PFS 28mo, OS benefit</td>
                        <td>ILD 10-15%, nausea 70%</td>
                        <td>Pulmonary toxicity, bias in open-label</td>
                    </tr>
                    <tr>
                        <td><strong>3L+</strong></td>
                        <td>T-DM1/tucatinib (Approved)</td>
                        <td>ORR 40-50%, PFS 7-9mo, OS 30mo</td>
                        <td>Thrombocytopenia 20%, diarrhea 40%</td>
                        <td>Cumulative toxicity, limited options</td>
                    </tr>
                    <tr>
                        <td><strong>China/Japan</strong></td>
                        <td>Lapatinib/cape common 2L/3L</td>
                        <td>Similar PFS/OS but access-limited</td>
                        <td>Hand-foot syndrome 30%, under-reported AEs</td>
                        <td>Cost, inflated PROs</td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Regional SoC Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>US/EU (FDA/EMA-approved):</strong> First-line is THP (trastuzumab + pertuzumab + taxane, PFS ~18-24 months, OS ~57 months from PERUSE/PERTAIN); second-line T-DXd (PFS ~28 months, OS benefit in DESTINY-Breast03); third-line T-DM1 or tucatinib combos (PFS ~7-9 months)</li>
                    <li>• <strong>Liver Metastases:</strong> For liver metastases, T-DXd is favored for visceral control (ORR ~79%)</li>
                    <li>• <strong>Efficacy Landmarks:</strong> T-DXd ORR 79%, PFS 28 months; safety includes ILD (10-15%)</li>
                    <li>• <strong>China (NMPA-approved):</strong> Similar but more lapatinib/capecitabine in later lines (PFS ~5 months)</li>
                    <li>• <strong>Japan (PMDA):</strong> Emphasizes oral regimens like tucatinib (PFS ~7 months in HER2CLIMB)</li>
                    <li>• <strong>Global Weaknesses:</strong> Cost barriers in Asia, small effects in mutants, under-reported AEs culturally</li>
                    <li>• <strong>DV Positioning:</strong> Disitamab vedotin's niche in liver mets addresses squishiness post-taxane/trastuzumab</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://daiichisankyo.us/press-releases/-/article/enhertu-plus-pertuzumab-granted-breakthrough-therapy-designation-in-the-us-as-first-line-therapy-for-patients-with-her2-positive-metastatic-breast-cancer" target="_blank" class="link-btn">DESTINY Updates</a> | 
                <a href="https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-demonstrated-highly-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-THP-as-1st-line-therapy-for-patients-with-HER2-positive-metastatic-breast-cancer.html" target="_blank" class="link-btn">THP Data</a>
            </div>
        </div>
    </div>

    <!-- 3. Probability of Technical & Regulatory Success -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>3. Probability of Technical & Regulatory Success (PTRS)</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">PTRS Assessment</h4>
                <p class="detail-text">
                    Research suggests Disitamab vedotin has a moderate probability of global regulatory success (around 40-50%) for HER2-positive metastatic breast cancer with liver metastases, based on its narrow Chinese approval and the need for new trials against current standards like trastuzumab deruxtecan, though its favorable safety profile (low ILD risk) could differentiate it in later lines.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Overall PTRS</div>
                    <div class="metric-value">40-50%</div>
                    <div class="metric-detail">Global regulatory success</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Phase II PTSR</div>
                    <div class="metric-value">~37%</div>
                    <div class="metric-detail">GlobalData solid tumors</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">LoA HER2+ mBC</div>
                    <div class="metric-value">40-50%</div>
                    <div class="metric-detail">Given China approval</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">AI Score</div>
                    <div class="metric-value">45%</div>
                    <div class="metric-detail">Regulatory probability</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">PTRS Components & Adjustments</h4>
                <ul class="space-y-2">
                    <li>• <strong>Base Assessment:</strong> PTRS for Disitamab vedotin draws from its HER2-targeting mechanism (precedents like T-DXd), strong Phase 3 PFS (HR 0.56), and favorable regulatory climate for ADCs amid unmet needs in visceral disease</li>
                    <li>• <strong>Benchmark Data:</strong> GlobalData estimates Phase II PTSR ~37% for solid tumors; BioMedTracker analogs ~45% for ADCs in crowded spaces</li>
                    <li>• <strong>SME Overlays:</strong> Adjust upward (+10-15%) for clean safety (no ILD vs competitors) and downward (-5-10%) for older control arm</li>
                    <li>• <strong>Biology Input:</strong> Bystander effect in HER2-low populations</li>
                    <li>• <strong>Design Input:</strong> Randomized but niche indication</li>
                    <li>• <strong>Endpoint Input:</strong> PFS surrogate accepted by regulators</li>
                    <li>• <strong>Climate Input:</strong> BTD precedent established</li>
                    <li>• <strong>Recent Updates:</strong> Updates post-2025 NMPA and SABCS boost ~10%, with AI scores at 45% regulatory</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-solid-tumor-likelihood-of-approval/" target="_blank" class="link-btn">GlobalData Analysis</a> | 
                <a href="https://www.intelligencia.ai/data-backed-probability-of-technical-and-regulatory-success-heres-how-ai-supports-critical-decisions-in-drug-development/" target="_blank" class="link-btn">AI PTRS Models</a>
            </div>
        </div>
    </div>

    <!-- 4. Competitive Intelligence -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>4. Competitive Intelligence (esp. China-origin programs)</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Competitive Landscape Summary</h4>
                <p class="detail-text">
                    Competitive landscape includes several China-origin HER2 ADCs like Alphamab's KN026 in Phase 3, with inflation risks in early data; Disitamab vedotin's MMAE payload offers a potential edge in safety over deruxtecan-based rivals but faces challenges in differentiating efficacy. The HER2 ADC space features ~15 assets, with Disitamab vedotin differentiated by low ILD but higher neuropathy.
                </p>
            </div>

            <table class="trial-table mt-4">
                <thead>
                    <tr>
                        <th>Competitor</th>
                        <th>Mechanism/Phase/Geography</th>
                        <th>Trial Design/Key Data</th>
                        <th>Funding/Licensing</th>
                        <th>Inflation Risk</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>T-DXd</strong></td>
                        <td>HER2/Approved/Global</td>
                        <td>DESTINY: PFS 28mo</td>
                        <td>Daiichi/AZ</td>
                        <td>Low</td>
                    </tr>
                    <tr>
                        <td><strong>KN026</strong></td>
                        <td>Biparatopic HER2/Phase 3/China</td>
                        <td>Combo: ORR superior preclinical</td>
                        <td>Alphamab internal</td>
                        <td>High (China-only)</td>
                    </tr>
                    <tr>
                        <td><strong>HLX22</strong></td>
                        <td>HER2/Phase 3/China-EU</td>
                        <td>Mono: Safety focus</td>
                        <td>Henlius + GeneQuantum</td>
                        <td>Medium (bridging)</td>
                    </tr>
                    <tr>
                        <td><strong>Anbenitamab</strong></td>
                        <td>HER2/Phase 3/China</td>
                        <td>Potential US bridging</td>
                        <td>CSPC</td>
                        <td>High</td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">China-Origin Program Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>Key Competitors:</strong> T-DXd (Phase 3 global, geography broad); T-DM1 (approved)</li>
                    <li>• <strong>Alphamab's KN026:</strong> Biparatopic HER2, Phase 3 China, funding internal, out-licensing to West planned, high inflation in early ORR data</li>
                    <li>• <strong>Henlius' HLX22:</strong> Phase 3, licensed from GeneQuantum, confirmatory EU trials</li>
                    <li>• <strong>CSPC's Anbenitamab:</strong> Phase 3 China, potential US bridging</li>
                    <li>• <strong>CT.gov/NMPA Registry:</strong> ~10 China-led (Phases 1-3, single-arm designs)</li>
                    <li>• <strong>Deals:</strong> Henlius $undisclosed for HLX22</li>
                    <li>• <strong>Inflation Risk:</strong> High in China-only (over-reported PROs), mitigated by global confirmatories</li>
                    <li>• <strong>Competitive Threat:</strong> Ahead programs like KN026 could undercut costs</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.prnewswire.com/apac/news-releases/alphamab-oncology-reports-2025-interim-results-and-business-highlights-302541640.html" target="_blank" class="link-btn">Alphamab Updates</a> | 
                <a href="https://www.henlius.com/en/NewsDetails-5387-26.html" target="_blank" class="link-btn">Henlius Pipeline</a> | 
                <a href="https://clinicaltrials.gov/study/NCT04879361" target="_blank" class="link-btn">ClinicalTrials.gov</a>
            </div>
        </div>
    </div>

    <!-- 5. Geographic/Cultural Biases -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>5. Geographic / Cultural Biases (AE & PRO reporting)</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Bias Assessment</h4>
                <p class="detail-text">
                    Geographic biases in adverse event reporting, such as under-reporting in China due to cultural factors, could affect trial interpretations, though no major issues noted in Disitamab vedotin studies; mitigations like global enrollment are planned for ex-China development.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Asia Enrollment</div>
                    <div class="metric-value">~100%</div>
                    <div class="metric-detail">RC48-C006 trial</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">AE Under-reporting</div>
                    <div class="metric-value">20-30%</div>
                    <div class="metric-detail">Lower vs US</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">PRO Inflation</div>
                    <div class="metric-value">Noted</div>
                    <div class="metric-detail">Physician respect factor</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Missingness Rate</div>
                    <div class="metric-value">10-15%</div>
                    <div class="metric-detail">High in China trials</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Bias Details & Mitigation</h4>
                <ul class="space-y-2">
                    <li>• <strong>Trial Composition:</strong> Chinese trials (e.g., RC48-C006) involve ~100% Asia enrollment</li>
                    <li>• <strong>Under-reporting Pattern:</strong> Flagging under-reporting of AEs (20-30% lower vs US, zeros in PROs due to physician respect) and over-reported benefits</li>
                    <li>• <strong>Data Quality:</strong> Missingness high (10-15%); investigator-reported prioritized over PRO</li>
                    <li>• <strong>Mitigation Strategy:</strong> US repeat in bridging (Pfizer plans), adapted tools, training</li>
                    <li>• <strong>Efficacy Impact:</strong> Inflated efficacy in China (ORR 38% may adjust lower globally)</li>
                    <li>• <strong>DV-Specific Assessment:</strong> No major DV-specific bias, but general Asian under-reporting noted</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10417093/" target="_blank" class="link-btn">Geographic Bias Analysis</a> | 
                <a href="https://x.com/Matsuda_PhDPhD/status/1922870508678414748" target="_blank" class="link-btn">Cultural Factors in Reporting</a>
            </div>
        </div>
    </div>

    <!-- 6. Economic/Financing Thresholds -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>6. Economic / Financing Thresholds</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Financial Assessment</h4>
                <p class="detail-text">
                    RemeGen's partnerships, including with Pfizer for ex-China rights, bolster financing with upfront payments extending cash runway into 2026, supporting Phase 3 costs estimated at hundreds of millions without apparent progression thresholds concerns.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Phase 3 Cost</div>
                    <div class="metric-value">$200-300M</div>
                    <div class="metric-detail">Estimated range</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Cash Runway</div>
                    <div class="metric-value">2026</div>
                    <div class="metric-detail">Post-partnerships</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Vor Bio Deal</div>
                    <div class="metric-value">$125M</div>
                    <div class="metric-detail">Upfront for telitacicept</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Threshold Status</div>
                    <div class="metric-value">Aligned</div>
                    <div class="metric-detail">Proceeded post-approval</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Financing Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>Phase 3 Costs:</strong> ~$200-300M, covered by RemeGen's revenue growth (strong H1 2025 from products)</li>
                    <li>• <strong>Partnership Support:</strong> Vor Bio ($125M upfront for telitacicept, extending runway to 2026)</li>
                    <li>• <strong>Balance Sheet:</strong> Cash positive post-deals</li>
                    <li>• <strong>Pfizer Funding:</strong> Pfizer funds ex-China (Seagen acquisition)</li>
                    <li>• <strong>Threshold Alignment:</strong> Thresholds aligned (proceeded post-China approval)</li>
                    <li>• <strong>Funding Structure:</strong> Self/partnered funding, no red flags</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.msn.com/en-us/money/savingandinvesting/remegen-co-ltd-reports-strong-revenue-growth-and-key-product-approvals-in-2025/ar-AA1L29Xa" target="_blank" class="link-btn">RemeGen Financials</a> | 
                <a href="https://www.bioworld.com/articles/721838-after-axing-95-workforce-vor-bets-4b-on-remegens-telitacicept" target="_blank" class="link-btn">Vor Bio Deal</a>
            </div>
        </div>
    </div>

    <!-- 7. Operational Disclosure -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7. Operational Disclosure / Documentation</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Documentation Status</h4>
                <p class="detail-text">
                    Operational disclosures on ClinicalTrials.gov for key trials appear consistent, with protocol updates reflecting standard amendments and no evident gaps in safety or design reporting.
                </p>
            </div>

            <div class="data-card">
                <h4 class="font-semibold mb-2">Disclosure Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>NCT03500380 Entries:</strong> Consistent from Protocol v1.0 (2018) to amendments for enrollment/safety, updates timely</li>
                    <li>• <strong>IB Alignment:</strong> IB aligns (no DLTs at 2mg/kg); no gaps in cohorts/signals</li>
                    <li>• <strong>Minor Mismatches:</strong> Sample size variations explained by feasibility</li>
                    <li>• <strong>Safety Reporting:</strong> No undisclosed safety signals</li>
                    <li>• <strong>Design Changes:</strong> Standard protocol amendments documented</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://clinicaltrials.gov/study/NCT03500380" target="_blank" class="link-btn">NCT03500380</a> | 
                <a href="https://www.clinicaltrials.gov/study/NCT05904964" target="_blank" class="link-btn">Trial Registry</a>
            </div>
        </div>
    </div>

    <!-- 8. Line-of-Therapy / Label Implications -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>8. Line-of-Therapy / Label Implications</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Positioning Assessment</h4>
                <p class="detail-text">
                    Evidence leans toward Disitamab vedotin being positioned for third-line or later therapy globally, similar to precedents like trastuzumab deruxtecan in post-trastuzumab settings, but with potential for a biomarker-defined label in HER2-low populations if additional data support broader use.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">China Label</div>
                    <div class="metric-value">3L+</div>
                    <div class="metric-detail">Post-trastuzumab/taxane</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">FDA Likely</div>
                    <div class="metric-value">3L</div>
                    <div class="metric-detail">Post-T-DXd HER2+</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">EMA Positioning</div>
                    <div class="metric-value">2L HER2-low</div>
                    <div class="metric-detail">If data supports</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">SoC Clarity</div>
                    <div class="metric-value">Clear 1L</div>
                    <div class="metric-detail">THP OS data solid</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Label Strategy Details</h4>
                <ul class="space-y-2">
                    <li>• <strong>Intended Line:</strong> 3L+ per China trial design</li>
                    <li>• <strong>Precedents:</strong> T-DXd 2L post-PERTAIN supports if vs modern SoC</li>
                    <li>• <strong>FDA/EMA Likely:</strong> 3L post-T-DXd in HER2+ or 2L HER2-low</li>
                    <li>• <strong>SoC Clarity:</strong> 1L (THP OS data) favors later lines</li>
                    <li>• <strong>Combo Potential:</strong> Combo-only if PD-1 synergies key</li>
                    <li>• <strong>Biomarker Strategy:</strong> Potential for biomarker-defined label in HER2-low populations</li>
                </ul>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.bcrf.org/blog/asco-2025-metastatic-breast-cancer-updates/" target="_blank" class="link-btn">ASCO 2025 Updates</a> | 
                <a href="https://www.remegen.com/" target="_blank" class="link-btn">RemeGen Pipeline</a>
            </div>
        </div>
    </div>

    <!-- Investment Summary -->
    <div class="data-card mt-6">
        <h3 class="text-xl font-bold mb-4">Investment Committee Decision Points</h3>
        
        <div class="metric-grid">
            <div class="metric-card">
                <div class="metric-label">Global PTRS</div>
                <div class="metric-value" style="color: #ffc107;">40-50%</div>
                <div class="metric-detail">Moderate probability</div>
            </div>
            <div class="metric-card">
                <div class="metric-label">Line Position</div>
                <div class="metric-value">3L+</div>
                <div class="metric-detail">Post-T-DXd likely</div>
            </div>
            <div class="metric-card">
                <div class="metric-label">Safety Edge</div>
                <div class="metric-value" style="color: #28a745;">No ILD</div>
                <div class="metric-detail">vs T-DXd 10-15%</div>
            </div>
            <div class="metric-card">
                <div class="metric-label">Financial Health</div>
                <div class="metric-value" style="color: #28a745;">2026</div>
                <div class="metric-detail">Cash runway secured</div>
            </div>
        </div>

        <p class="detail-text mt-4">
            <strong>Key Investment Thesis:</strong> Disitamab vedotin offers a differentiated safety profile in a crowded HER2 ADC space, with established China approval providing validation. The moderate PTRS reflects the need for new trials against modern controls, but the absence of ILD toxicity creates a clear positioning opportunity in patients who cannot tolerate T-DXd. With Pfizer's backing for global development and RemeGen's strong China execution, the asset presents a balanced risk-reward profile for late-stage oncology investment.
        </p>
    </div>
</div>
            <!-- Clinical & Regulatory Tab -->
            <div id="clinical" class="tab-content">
                <!-- DISITAMAB VEDOTIN (RC48) VISUAL SUMMARY -->
<div class="subsection-title">Regulatory & Clinical Overview - Disitamab Vedotin</div>

<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 16px; margin-bottom: 20px;">
    
    <!-- LEFT: Regulatory Timeline -->
    <div class="data-card">
        <h5 class="font-semibold text-green-700 mb-3" style="font-size: 14px;">Regulatory Pathway</h5>
        
        <div style="position: relative; padding-left: 24px;">
            <div style="position: absolute; left: 6px; top: 20px; bottom: 20px; width: 2px; background: linear-gradient(180deg, #667eea 0%, #28a745 60%, #ffc107 100%);"></div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #667eea; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2020</div>
                <div style="font-size: 12px; color: #424242;"><strong>FDA BTD</strong> • Urothelial</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #667eea; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2024</div>
                <div style="font-size: 12px; color: #424242;"><strong>NMPA Priority</strong> • Breast</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #28a745; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">Dec 2024</div>
                <div style="font-size: 12px; color: #424242;"><strong>Phase 3 Success</strong> ✓</div>
                <div style="font-size: 11px; color: #28a745; margin-left: 0;">HR 0.56, p=0.014</div>
            </div>
            
            <div style="margin-bottom: 12px;">
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #28a745; border-radius: 50%; border: 2px solid white;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">May 2025</div>
                <div style="font-size: 12px; color: #424242;"><strong>NMPA Approved</strong></div>
                <div style="font-size: 11px; color: #28a745;">HER2+ w/ liver mets</div>
            </div>
            
            <div>
                <div style="position: absolute; left: 2px; width: 10px; height: 10px; background: #ffc107; border-radius: 50%; border: 2px solid white; animation: pulse 2s infinite;"></div>
                <div style="font-size: 11px; color: #6c757d; font-weight: 600;">2026-2027</div>
                <div style="font-size: 12px; color: #424242;"><strong>FDA/EMA Filing</strong></div>
                <div style="font-size: 11px; color: #ffc107;">Global trials needed</div>
            </div>
        </div>
    </div>
    
    <!-- RIGHT: Trial Portfolio -->
    <div class="data-card">
        <h5 class="font-semibold text-green-700 mb-3" style="font-size: 14px;">Clinical Development</h5>
        
        <div style="display: flex; flex-direction: column; gap: 8px;">
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #e3f2f0;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f7f6; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #0a6b5e;">Ph 1/2</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">China Studies</div>
                    <div style="font-size: 11px; color: #6c757d;">Multiple • ORR 43% HER2+</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #e3f2f0; color: #0a6b5e; border-radius: 4px; font-weight: 600;">✓</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #d4f4ec; border-radius: 6px; border: 1px solid #28a745;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #28a745; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: white;">Ph 3</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">RC48-C006</div>
                    <div style="font-size: 11px; color: #28a745; font-weight: 600;">n=104 • PFS 9.9 vs 4.9mo</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #28a745; color: white; border-radius: 4px; font-weight: 600;">APPROVED</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #667eea;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f4ff; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #667eea;">Global</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">Pfizer Studies</div>
                    <div style="font-size: 11px; color: #6c757d;">Post-T-DXd • HER2-low</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #667eea; color: white; border-radius: 4px; font-weight: 600;">PLANNED</span>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; padding: 8px; background: #f8fffe; border-radius: 6px; border: 1px solid #e3f2f0;">
                <div style="flex-shrink: 0; width: 40px; height: 40px; background: #f0f7f6; border-radius: 6px; display: flex; align-items: center; justify-content: center; margin-right: 10px;">
                    <span style="font-size: 10px; font-weight: 700; color: #0a6b5e;">Combo</span>
                </div>
                <div style="flex: 1;">
                    <div style="font-size: 12px; font-weight: 600; color: #333;">PD-1 Studies</div>
                    <div style="font-size: 11px; color: #6c757d;">+ Toripalimab ongoing</div>
                </div>
                <div style="flex-shrink: 0;">
                    <span style="font-size: 10px; padding: 2px 6px; background: #ffc107; color: #333; border-radius: 4px; font-weight: 600;">ACTIVE</span>
                </div>
            </div>
        </div>
    </div>
</div>

<div class="highlight-box" style="padding: 12px 16px;">
    <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 16px; text-align: center;">
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #28a745;">2X</div>
            <div style="font-size: 11px; color: #6c757d;">PFS Benefit</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #0a6b5e;">No ILD</div>
            <div style="font-size: 11px; color: #6c757d;">vs T-DXd 10-15%</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #667eea;">3</div>
            <div style="font-size: 11px; color: #6c757d;">Indications</div>
        </div>
        <div>
            <div style="font-size: 20px; font-weight: 700; color: #ffc107;">40-50%</div>
            <div style="font-size: 11px; color: #6c757d;">Global PTRS</div>
        </div>
    </div>
</div>

<div style="height: 30px;"></div>

                <div class="section-title">1. Clinical & Regulatory Diligence</div>
                
                <!-- Trial Design & Protocol -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.1 Trial Design & Protocol</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">RC48-C006 Phase 3 Design Overview</h4>
                            <p class="detail-text">
                                RC48-C006 (NCT03500380) is an open-label trial in HER2-positive metastatic breast cancer with liver metastases. The trial randomized 104 patients (53 DV; 51 lapatinib+capecitabine) who had prior trastuzumab and taxane. The primary endpoint was progression-free survival (PFS) by independent review; secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Primary Endpoint</div>
                                <div class="metric-value">PFS</div>
                                <div class="metric-detail">By independent review</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Sample Size</div>
                                <div class="metric-value">104</div>
                                <div class="metric-detail">53 DV vs 51 control</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Comparator</div>
                                <div class="metric-value">Lapatinib+Cape</div>
                                <div class="metric-detail">Then-standard in China</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Stratification</div>
                                <div class="metric-value">Liver Mets</div>
                                <div class="metric-detail">All patients had liver mets</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Geographic Distribution:</strong> The pivotal study was conducted entirely in China. This provides robust data for NMPA but means Western populations were not included – any differences in patient demographics or standards of care will need bridging.
                        </p>

                        <p class="detail-text">
                            <strong>Statistical Power:</strong> The Phase 3, with ~100 patients, was relatively small. It was powered to detect a PFS hazard ratio ~0.5–0.6. Indeed, it achieved an HR of 0.56, p=0.0143.
                        </p>

                        <p class="detail-text">
                            <strong>Crossover Design:</strong> Patients on lapatinib+capecitabine could receive DV after progression. This ethical choice, while beneficial to patients, complicates OS interpretation (diminishing OS difference).
                        </p>

                        <div class="reference-list">
                            Sources: <a href="https://clinicaltrials.gov/ct2/show/NCT03500380" target="_blank" class="link-btn">ClinicalTrials.gov NCT03500380</a> | 
                            <a href="https://www.adcreview.com" target="_blank" class="link-btn">ADC Review</a>
                        </div>
                    </div>
                </div>

                <!-- Clinical Efficacy Results -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.2 Clinical Efficacy & Data Quality</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Phase 3 Primary Endpoint Achievement</h4>
                            <p class="detail-text">
                                DV significantly improved PFS versus lapatinib+capecitabine: 9.9 vs 4.9 months (HR 0.56, 95% CI 0.35–0.90, P≈0.01). This ~5-month PFS gain is clinically meaningful in this hard-to-treat subgroup.
                            </p>
                        </div>

                        <canvas id="pfsChart" class="chart-container"></canvas>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Median PFS (DV)</div>
                                <div class="metric-value">9.9 mo</div>
                                <div class="metric-detail">vs 4.9 mo control</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Hazard Ratio</div>
                                <div class="metric-value">0.56</div>
                                <div class="metric-detail">95% CI: 0.35-0.90, p=0.0143</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">ORR (Phase 3)</div>
                                <div class="metric-value">~38%</div>
                                <div class="metric-detail">vs ~14% control</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Risk Reduction</div>
                                <div class="metric-value">44%</div>
                                <div class="metric-detail">In progression/death</div>
                            </div>
                        </div>

                        <div class="subsection-title">Phase 1/2 Signal Finding</div>
                        <p class="detail-text">
                            In pooled Phase 1/Ib results, ORR at RP2D (2.0 mg/kg) reached 42.9% in HER2-positive and 33.3% in HER2-low advanced breast cancer. Median PFS was ~5.7 months in HER2+ and ~5.1 months in HER2-low patients. These outcomes, achieved in heavily pretreated populations (88% had ≥3 prior lines), indicated a clear anti-tumor effect even among HER2-low tumors.
                        </p>

                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>Population</th>
                                    <th>ORR</th>
                                    <th>Median PFS</th>
                                    <th>Prior Lines</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>HER2-positive (Phase 1/2)</td>
                                    <td>42.9%</td>
                                    <td>5.7 months</td>
                                    <td>≥3 (88%)</td>
                                </tr>
                                <tr>
                                    <td>HER2-low (Phase 1/2)</td>
                                    <td>33.3%</td>
                                    <td>5.1 months</td>
                                    <td>≥3 (85%)</td>
                                </tr>
                                <tr>
                                    <td>HER2+ Liver Mets (Phase 3)</td>
                                    <td>38%</td>
                                    <td>9.9 months</td>
                                    <td>≥2 (100%)</td>
                                </tr>
                            </tbody>
                        </table>

                        <p class="detail-text mt-4">
                            <strong>Overall Survival Data:</strong> At the cutoff (Dec 2023), median OS was not reached on DV vs 25.9 months on control, with a trend favoring DV (HR ~0.56). However, due to cross-over, the true OS benefit may be underestimated. Longer follow-up is needed; updated OS is expected in late 2025.
                        </p>

                        <p class="detail-text">
                            <strong>Subgroup Analyses:</strong> The Phase 3 is narrowly focused (all patients had liver metastases), so subgroup analyses were limited. An exploratory cut by HER2 expression level (IHC 3+ vs 2+) has not been reported but all patients were HER2-positive by standard criteria.
                        </p>

                        <div class="reference-list">
                            Sources: SABCS 2024 Presentation | RemeGen Corporate Announcement | PubMed PMID: 38940019
                        </div>
                    </div>
                </div>

                <!-- Safety Profile -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.3 Safety Profile & Tolerability</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Overall Safety Summary</h4>
                            <p class="detail-text">
                                Disitamab vedotin's toxicity profile is manageable and in line with other MMAE-based ADCs. In the Phase 3, no new safety signals emerged. Importantly, DV has not shown the interstitial lung disease (ILD) signal that is associated with trastuzumab deruxtecan.
                            </p>
                        </div>

                        <table class="ae-table">
                            <thead>
                                <tr>
                                    <th>Adverse Event</th>
                                    <th>All Grades (%)</th>
                                    <th>Grade ≥3 (%)</th>
                                    <th>Clinical Significance</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>AST elevation</td>
                                    <td>~46%</td>
                                    <td><5-10%</td>
                                    <td>Mostly transient</td>
                                </tr>
                                <tr>
                                    <td>ALT elevation</td>
                                    <td>~42%</td>
                                    <td><5-10%</td>
                                    <td>Transient</td>
                                </tr>
                                <tr>
                                    <td>Neutropenia</td>
                                    <td>~50-55%</td>
                                    <td>17-19%</td>
                                    <td>Manageable with G-CSF</td>
                                </tr>
                                <tr>
                                    <td>Peripheral neuropathy</td>
                                    <td>~45-50%</td>
                                    <td>5.9%</td>
                                    <td>MMAE class effect</td>
                                </tr>
                                <tr>
                                    <td>Nausea</td>
                                    <td>~30%</td>
                                    <td>One patient</td>
                                    <td>Mostly Grade 1-2</td>
                                </tr>
                                <tr>
                                    <td>Fatigue</td>
                                    <td>~25%</td>
                                    <td>Rare</td>
                                    <td>Manageable</td>
                                </tr>
                                <tr>
                                    <td>ILD/Pneumonitis</td>
                                    <td>0%</td>
                                    <td>0%</td>
                                    <td>Key differentiator vs T-DXd</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Treatment-Related Deaths</div>
                                <div class="metric-value">0</div>
                                <div class="metric-detail">Across all studies</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Discontinuation Rate</div>
                                <div class="metric-value"><2%</div>
                                <div class="metric-detail">Due to TRAEs</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Grade ≥3 TRAEs</div>
                                <div class="metric-value">~36.5%</div>
                                <div class="metric-detail">In combination studies</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Febrile Neutropenia</div>
                                <div class="metric-value"><5%</div>
                                <div class="metric-detail">Rare occurrence</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Key Safety Differentiator:</strong> No cases of severe drug-induced liver injury have been reported – liver enzyme rises tended to be transient. Grade ≥3 gamma-GT elevation occurred in 13.2%. Only ~0.7% had severe neurotoxicity (Grade 4).
                        </p>

                        <p class="detail-text">
                            <strong>Dose Modifications:</strong> Only 1 patient (<2%) discontinued due to TRAE. Only 1 patient required dose reduction (Grade 3 nausea). The dose of DV (2 mg/kg q2w) was set to balance efficacy and neuropathy risk.
                        </p>
                    </div>
                </div>

                <!-- Regulatory Status -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.4 Regulatory Status & Interactions</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="regulatory-flow">
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>FDA BTD (UC)</strong>
                                <p class="text-sm mt-1">Granted 2020</p>
                                <p class="text-xs text-gray-500">Urothelial cancer</p>
                            </div>
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>NMPA Priority Review</strong>
                                <p class="text-sm mt-1">2024</p>
                                <p class="text-xs text-gray-500">Breast cancer</p>
                            </div>
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>Phase 3 Positive</strong>
                                <p class="text-sm mt-1">RC48-C006 Met Primary</p>
                                <p class="text-xs text-gray-500">Dec 2024</p>
                            </div>
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>NMPA Approval</strong>
                                <p class="text-sm mt-1">May 9, 2025</p>
                                <p class="text-xs text-gray-500">HER2+ BCLM</p>
                            </div>
                            <div class="flow-node active">
                                <strong>Global Development</strong>
                                <p class="text-sm mt-1">Pfizer Leading</p>
                                <p class="text-xs text-gray-500">2025-2026</p>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>China (NMPA):</strong> Leveraging the Phase 3 results, RemeGen filed for approval in China in Oct 2024. The NMPA granted priority review and Breakthrough Therapy designation for this indication. Approval was granted on May 9, 2025 for "HER2-positive advanced breast cancer with liver metastasis, after trastuzumab and taxane." This label is tightly aligned to the trial population, ensuring on-label use matches evidence. It's the first ADC approved specifically for HER2+ breast cancer with liver mets globally.
                        </p>

                        <p class="detail-text">
                            <strong>FDA (USA):</strong> Disitamab vedotin already has a relationship with FDA via urothelial cancer: FDA granted Breakthrough Therapy Designation (BTD) in 2020 for HER2+ metastatic urothelial carcinoma, along with IND clearance and Fast Track for that setting. However, no BTD yet in breast cancer – likely because no U.S. breast cancer trials have reported.
                        </p>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Regulatory Risk Considerations</h4>
                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>Comparator Issue:</strong> Phase 3 used an outdated control (lapatinib+capecitabine), risking FDA/EMA concern that DV wasn't tested against current SOC.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>CMC Status:</strong> NDA acceptance indicates adequate CMC data. Vepdegestrant is a synthetic small molecule (PROTAC), larger than typical kinase inhibitors.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>Patient Population:</strong> Small trial (N=104) primarily in Chinese patients – questions of generalizability.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Companion Diagnostic:</strong> No new diagnostic needed beyond HER2 testing. In HER2-low, defining eligibility will rely on standard IHC 1+ or 2+ scoring.
                                </div>
                            </div>
                        </div>

                        <div class="reference-list">
                            Sources: FDA Breakthrough Therapy Announcement | NMPA Approval Document | RemeGen SEC Filings
                        </div>
                    </div>
                </div>
            </div>

            <!-- Scientific & IP Tab -->
            <div id="scientific" class="tab-content">
                <div class="section-title">2. Scientific & Intellectual Property Diligence</div>

                <!-- Mechanism of Action -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.1 Mechanism of Action & Scientific Rationale</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Novel ADC Technology</h4>
                            <p class="detail-text">
                                Disitamab vedotin is an antibody-drug conjugate comprising a humanized anti-HER2 IgG1 monoclonal antibody conjugated to MMAE (a tubulin inhibitor) via a cleavable linker. The antibody (sometimes dubbed hertuzumab) binds a unique epitope on HER2 distinct from trastuzumab's binding site. It has higher affinity for low-HER2-expressing cells than trastuzumab, which is crucial for efficacy in HER2-"low" tumors.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Target</div>
                                <div class="metric-value">HER2</div>
                                <div class="metric-detail">Unique epitope</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Payload</div>
                                <div class="metric-value">MMAE</div>
                                <div class="metric-detail">Tubulin inhibitor</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Linker</div>
                                <div class="metric-value">Val-Cit</div>
                                <div class="metric-detail">Cleavable dipeptide</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">DAR</div>
                                <div class="metric-value">~4</div>
                                <div class="metric-detail">Drug-antibody ratio</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Mechanism Details:</strong> Upon HER2 binding, the ADC is internalized and the linker (a valine-citrulline dipeptide similar to that used in Adcetris) is cleaved intracellularly to release MMAE. MMAE induces cell death by disrupting microtubules. Additionally, DV can exert a bystander effect: MMAE can diffuse to kill neighboring tumor cells, important in heterogenous tumors where not every cell highly expresses HER2.
                        </p>

                        <p class="detail-text">
                            <strong>Scientific Validation:</strong> HER2 is a well-validated target in breast cancer; its role in driving tumor growth is established over decades. Uniquely, DV capitalizes on HER2 expression across a spectrum – even tumors with low levels can be targeted, expanding the reach beyond HER2-amplified cancers. This concept was later dramatically validated by trastuzumab deruxtecan in HER2-low breast cancer (DESTINY-Breast04).
                        </p>

                        <p class="detail-text">
                            <strong>Preclinical Data:</strong> In xenograft models, disitamab vedotin showed potent antitumor activity against both HER2-high and HER2-low tumors. Notably, DV outperformed T-DM1 in certain HER2-low breast cancer models, likely due to its ability to kill HER2-negative bystander cells.
                        </p>
                    </div>
                </div>

                <!-- Differentiation Analysis -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.2 Scientific Differentiation & Competitive Edge</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>Feature</th>
                                    <th>Disitamab Vedotin</th>
                                    <th>T-DXd (Enhertu)</th>
                                    <th>T-DM1 (Kadcyla)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Payload</td>
                                    <td>MMAE</td>
                                    <td>DXd (topoisomerase I)</td>
                                    <td>DM1 (maytansinoid)</td>
                                </tr>
                                <tr>
                                    <td>ILD Risk</td>
                                    <td>None observed</td>
                                    <td>~10-15% (some fatal)</td>
                                    <td>Low</td>
                                </tr>
                                <tr>
                                    <td>Neuropathy</td>
                                    <td>~45% (Grade 3: 6%)</td>
                                    <td>Low</td>
                                    <td>Moderate</td>
                                </tr>
                                <tr>
                                    <td>HER2-low Activity</td>
                                    <td>ORR ~30-33%</td>
                                    <td>ORR ~52%</td>
                                    <td>Limited</td>
                                </tr>
                                <tr>
                                    <td>Bystander Effect</td>
                                    <td>Strong (MMAE diffuses)</td>
                                    <td>Very strong</td>
                                    <td>Limited</td>
                                </tr>
                                <tr>
                                    <td>Dosing</td>
                                    <td>2 mg/kg Q2W</td>
                                    <td>5.4 mg/kg Q3W</td>
                                    <td>3.6 mg/kg Q3W</td>
                                </tr>
                            </tbody>
                        </table>

                        <p class="detail-text mt-4">
                            <strong>Key Scientific Advantages:</strong> DV's early trials were among the first to show that HER2 "low" tumors respond to ADC therapy (ORR ~30% in HER2-low), reinforcing the drug's mechanistic rationale. Cross-resistance with trastuzumab or T-DM1 is not complete, since DV can work even after those agents – many Phase 1 patients had progressed on T-DM1 yet responded to DV.
                        </p>
                    </div>
                </div>

                <!-- Intellectual Property -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.3 Intellectual Property Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Patent Portfolio Overview</h4>
                            <p class="detail-text">
                                Disitamab vedotin's IP is jointly held by RemeGen and (through license) Seagen/Pfizer. According to Seagen's disclosures, there are eight key patents (U.S. and Europe) covering DV and related ADC technology, expiring between 2022 and 2034. RemeGen has publicized that RC48's invention patent was granted in China, U.S., EU, Japan, etc.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Core Patents</div>
                                <div class="metric-value">8</div>
                                <div class="metric-detail">US & Europe</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Patent Expiry</div>
                                <div class="metric-value">2034</div>
                                <div class="metric-detail">Base patents</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">With Extensions</div>
                                <div class="metric-value">~2039</div>
                                <div class="metric-detail">Potential PTE</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Global Coverage</div>
                                <div class="metric-value">12+</div>
                                <div class="metric-detail">Countries/regions</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Patent Components:</strong> The patents include: (1) the composition of matter on the DV antibody and its conjugate, (2) the linker-payload patents originally developed by Seagen (for the vedotin platform), and (3) method-of-use patents for DV in various HER2-expressing cancers.
                        </p>

                        <p class="detail-text">
                            <strong>Freedom to Operate:</strong> No blocking patents that would prevent DV's commercialization. HER2-targeting antibodies have long been patented (Genentech's Herceptin patents expired years ago). DV's antibody is novel enough not to infringe known sequences.
                        </p>

                        <p class="detail-text">
                            <strong>Seagen Partnership:</strong> DV combines the drug-linker technology originally developed by Seagen. By licensing DV to Seagen (now Pfizer), RemeGen ensured freedom to operate globally under those patents. The Daiichi Sankyo vs Seagen patent litigation does not involve DV directly.
                        </p>
                    </div>
                </div>

                <!-- Combination Potential -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.4 Combination Strategies & Future Development</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Combination Studies</h4>
                            
                            <p class="detail-text">
                                <strong>Immunotherapy Combinations:</strong> DV + anti-PD-1 (toripalimab or pembrolizumab) showed additive efficacy in early trials in urothelial cancer (ORR ~75%), hinting at immune activation. Preclinically, MMAE induces immunogenic cell death, potentially synergizing with immune checkpoint inhibitors.
                            </p>

                            <p class="detail-text">
                                <strong>Targeted Therapy Combinations:</strong> In breast cancer, combinations with CDK4/6 inhibitors for HR+ disease or with anti-VEGF agents are being explored. A Chinese Phase 2 reported better PFS with DV+antiangiogenic vs DV alone.
                            </p>

                            <p class="detail-text">
                                <strong>Safety in Combinations:</strong> DV's safety profile (no overlapping cardiotoxicity or ILD) makes it amenable to combos. Combining DV with endocrine therapy or checkpoint inhibitors did not significantly worsen toxicity in preliminary studies.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Commercial & Market Tab -->
            <div id="commercial" class="tab-content">
                <div class="section-title">3. Commercial & Market Diligence</div>

                <!-- Market Opportunity -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.1 Epidemiology & Market Sizing</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Addressable Market Overview</h4>
                            <p class="detail-text">
                                Globally, breast cancer is the most common cancer in women, with ~2.3 million new cases annually. In major markets, annual incidence is ~268k in the US, ~500k in Europe (EU-5), and ~416k in China (2020 data).
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Global BC Incidence</div>
                                <div class="metric-value">2.3M</div>
                                <div class="metric-detail">Annual new cases</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">HER2+ Prevalence</div>
                                <div class="metric-value">15-20%</div>
                                <div class="metric-detail">Of all breast cancers</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">HER2-low Prevalence</div>
                                <div class="metric-value">45-50%</div>
                                <div class="metric-detail">Of "HER2-negative"</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Liver Mets in HER2+</div>
                                <div class="metric-value">~45%</div>
                                <div class="metric-detail">Target population</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Patient Flow Analysis:</strong> HER2-positive metastatic breast cancer (MBC): ~15-20% of breast cancers overexpress HER2. With improved survival, prevalence is growing. In the US, an estimated ~50,000 patients have HER2+ MBC at any time. Each year, perhaps 10-15k patients progress to second-line or beyond (where DV would be used).
                        </p>

                        <p class="detail-text">
                            <strong>HER2-low Opportunity:</strong> This newly recognized group (HER2 IHC1+ or 2+/ISH–) constitutes ~45-50% of "HER2-negative" breast cancers. Essentially, HER2-low is very large: possibly ~50% of all breast cancers, which in metastatic setting translates to ~30-40k MBC patients in the US alone.
                        </p>

                        <p class="detail-text">
                            <strong>Duration of Therapy:</strong> DV is being positioned in late-line metastatic disease initially. The duration of therapy in metastatic setting is until progression: in trials DV's median treatment duration was ~6-7 months for responders. Some patients stayed on >1 year.
                        </p>
                    </div>
                </div>

                <!-- Competitive Landscape -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.2 Competitive Landscape Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">HER2-Targeted Therapy Landscape</h4>
                            
                            <p class="detail-text">
                                <strong>First-line HER2+:</strong> Standard is trastuzumab + pertuzumab + chemo (Cleopatra regimen), yielding median PFS ~18 months. DV is not positioned here currently.
                            </p>

                            <p class="detail-text">
                                <strong>Second-line HER2+:</strong> Enhertu (trastuzumab deruxtecan) is now the preferred agent based on DESTINY-Breast03, where it massively outperformed T-DM1 (PFS ~25 months vs 7 months). ORR ~79%, some complete responses.
                            </p>

                            <p class="detail-text">
                                <strong>Third-line HER2+:</strong> Options include Kadcyla (T-DM1) if not used prior, capecitabine-based chemo, tucatinib (HER2 TKI) + capecitabine + trastuzumab. Tucatinib triplet showed PFS ~7.6 months in 3rd line.
                            </p>
                        </div>

                        <table class="trial-table mt-4">
                            <thead>
                                <tr>
                                    <th>Drug</th>
                                    <th>Company</th>
                                    <th>Setting</th>
                                    <th>Key Efficacy</th>
                                    <th>Key Safety Issue</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>T-DXd (Enhertu)</td>
                                    <td>Daiichi/AZ</td>
                                    <td>2L HER2+</td>
                                    <td>PFS ~25 mo, ORR 79%</td>
                                    <td>ILD ~10-15%</td>
                                </tr>
                                <tr>
                                    <td>T-DM1 (Kadcyla)</td>
                                    <td>Roche</td>
                                    <td>2-3L HER2+</td>
                                    <td>PFS ~7 mo</td>
                                    <td>Thrombocytopenia</td>
                                </tr>
                                <tr>
                                    <td>Sacituzumab (Trodelvy)</td>
                                    <td>Gilead</td>
                                    <td>3L+ TNBC/HR+</td>
                                    <td>PFS ~5-6 mo</td>
                                    <td>Neutropenia, diarrhea</td>
                                </tr>
                                <tr>
                                    <td>ARX788</td>
                                    <td>Ambrx</td>
                                    <td>3L HER2+ (Ph3)</td>
                                    <td>PFS ~6.8 mo</td>
                                    <td>Under evaluation</td>
                                </tr>
                                <tr>
                                    <td>SYD985</td>
                                    <td>Byondis</td>
                                    <td>Late HER2+</td>
                                    <td>PFS ~7 mo (TULIP)</td>
                                    <td>Higher toxicity</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Competitive Advantages of DV</h4>
                            <ul class="space-y-2">
                                <li>• <strong>Safety differentiator:</strong> Enhertu's ILD (incidence ~10-15%, incl. fatal cases ~0.8%) scares some physicians. DV has no ILD signal.</li>
                                <li>• <strong>Lower cost in China:</strong> DV's annual cost is ¥210k ($30k), whereas imported Enhertu costs several times more.</li>
                                <li>• <strong>Liver metastasis indication:</strong> DV is specifically approved for HER2+ with liver mets in China – no other drug has that label.</li>
                                <li>• <strong>Combination potential:</strong> DV is already being combined with PD-1 inhibitors in trials.</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <!-- Pricing & Reimbursement -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.3 Pricing & Reimbursement Strategy</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">China Annual Cost</div>
                                <div class="metric-value">¥210k</div>
                                <div class="metric-detail">~$30,000 USD</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">NRDL Coverage</div>
                                <div class="metric-value">¥60k</div>
                                <div class="metric-detail">Patient out-of-pocket</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Expected US Price</div>
                                <div class="metric-value">$140-180k</div>
                                <div class="metric-detail">Annual WAC (projected)</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">vs Enhertu</div>
                                <div class="metric-value">15-20%</div>
                                <div class="metric-detail">Potential discount</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Current ADC Pricing Benchmarks:</strong> Enhertu (trastuzumab deruxtecan): WAC in the U.S. is roughly $2,300 per 100mg vial. Annual cost ~$200k. Kadcyla (T-DM1): WAC about $94k/year in the US. Trodelvy: Around $16k per cycle, or $180k/year list in US.
                        </p>

                        <p class="detail-text">
                            <strong>Reimbursement Strategy:</strong> DV was added to China's NRDL within months of approval for gastric and bladder cancer, meaning RemeGen agreed to a steep discount for volume. Being on NRDL means Chinese patients pay ~¥60k out-of-pocket, vastly undercutting Enhertu.
                        </p>

                        <p class="detail-text">
                            <strong>US/EU Positioning:</strong> Pfizer will likely price DV in line with other ADCs, perhaps slightly under Enhertu to incentivize use. If Enhertu is $150-200k/year, DV might be launched at ~$140k/year WAC in the US.
                        </p>
                    </div>
                </div>

                <!-- KOL & Market Access -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.4 KOL Perspectives & Market Development</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Key Opinion Leader Views</h4>
                            <p class="detail-text">
                                KOLs in breast oncology are already aware of disitamab vedotin from conference presentations (SABCS 2024). Top breast cancer experts noted that DV is the first ADC to show benefit in HER2+ patients with heavy liver tumor burden. Prof. Jiayu Wang stated DV provides "clinically meaningful benefit… and a manageable safety profile" for HER2+ with liver mets.
                            </p>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Chinese Market Execution:</strong> RemeGen's strategy in China included a sizable field force (180 oncology reps covering 374 hospitals) – this contributed to rapid uptake. DV has been approved for three indications in China (gastric, bladder, breast).
                        </p>

                        <p class="detail-text">
                            <strong>Western Market Strategy:</strong> Western KOLs will likely want to see data in post-Enhertu patients. If Pfizer generates even a modest single-arm study showing ~25% ORR in patients who progressed on Enhertu, that would impress physicians that DV is a valuable sequential option.
                        </p>

                        <p class="detail-text">
                            <strong>Guideline Inclusion:</strong> NCCN Guidelines will incorporate DV quickly if approved. For HER2+ metastatic disease progressed on ≥2 HER2 regimens: options would include T-DM1 (if not given), fam-trastuzumab deruxtecan (if not given), disitamab vedotin, or tucatinib-based regimen.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Financial & Strategic Tab -->
            <div id="financial" class="tab-content">
                <div class="section-title">4. Financial & Strategic Diligence</div>

                <!-- RemeGen Financials -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.1 Company Financials (RemeGen & Pfizer)</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">RemeGen Market Cap</div>
                                <div class="metric-value">HK$50B</div>
                                <div class="metric-detail">~$6.5B USD</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">2024 Revenue</div>
                                <div class="metric-value">RMB1.70B</div>
                                <div class="metric-detail">61.9% YoY growth</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">R&D Expenses</div>
                                <div class="metric-value">RMB1.54B</div>
                                <div class="metric-detail">~$215M USD</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Cash Position</div>
                                <div class="metric-value">RMB3.7B</div>
                                <div class="metric-detail">Mid-2025 (incl. ST inv)</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>RemeGen Financial Health:</strong> The company's revenues for 2024 were RMB1.70 billion ($240M), a 61.9% increase from 2023. This was driven by robust sales of Telitacicept (RC18) and the ramp-up of DV (RC48) in China. RemeGen is not yet profitable, but losses are narrowing: net loss before tax in 2024 was RMB1.468 billion, slightly less than 2023.
                        </p>

                        <p class="detail-text">
                            <strong>Cash Runway:</strong> With a burn rate (operating cash outflow) of RMB1.18B in 2024, they had ~RMB3.7B in cash (including short-term investments) after financing and revenues. Analysts project RemeGen will reach positive operating cash flow by 2025 and even a small profit (RMB895M profit forecast for 2025).
                        </p>

                        <p class="detail-text">
                            <strong>Stock Performance:</strong> RemeGen's stock price soared >600% in 2025, likely allowing capital raises. The stock surge suggests positive sentiment – they likely did place new H-shares in 2025 to refill coffers.
                        </p>
                    </div>
                </div>

                <!-- Partnership Economics -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.2 Partnership Economics (RemeGen-Seagen/Pfizer)</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                    <h4 class="font-semibold mb-2">2021 License Deal Terms</h4>
                    <p class="detail-text">
                        The 2021 license deal with Seagen was for $200M upfront and up to $2.4B in milestones, plus tiered royalties "from high single-digit to mid-teens" on ex-Asia sales. So far, RemeGen likely received the $200M upfront (in 2021, likely boosting that year's financials) and perhaps some early milestones.
                    </p>
                </div>

                <div class="metric-grid">
                    <div class="metric-card">
                        <div class="metric-label">Upfront Payment</div>
                        <div class="metric-value">$200M</div>
                        <div class="metric-detail">Received 2021</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Total Milestones</div>
                        <div class="metric-value">$2.4B</div>
                        <div class="metric-detail">Potential</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Royalty Range</div>
                        <div class="metric-value">High-single to mid-teens</div>
                        <div class="metric-detail">On ex-Asia sales</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Territory Split</div>
                        <div class="metric-value">Asia vs Rest</div>
                        <div class="metric-detail">RemeGen keeps Asia</div>
                    </div>
                </div>

                <p class="detail-text mt-4">
                    <strong>Milestone Structure:</strong> The big milestones (e.g., Phase 3 completion, first FDA approval, sales targets) are pending. If DV gets FDA approval, RemeGen stands to receive a regulatory milestone – possibly on the order of $100M+ judging by deal size. RemeGen will also get royalties on Pfizer's sales (perhaps ~10-15%).
                </p>

                <p class="detail-text">
                    <strong>Revenue Split:</strong> RemeGen owes no royalties for China sales – it owns that market exclusively. This means RemeGen's China revenue is all theirs (minus standard COGS). For Pfizer, the economic burden is the development and commercialization cost outside Asia plus paying those milestones/royalties.
                </p>

                <p class="detail-text">
                    <strong>Pfizer Strategic Commitment:</strong> Pfizer acquired Seagen for $43 billion in 2023, a bold bet on ADCs. Pfizer recently dropped some ADC programs (e.g., a B7-H4 ADC, with a $1B write-off), which raises the question of how much they prioritize DV. Notably, that write-off was for an internal Pfizer ADC that failed; DV's continuing development (with positive data) likely solidifies its place in Pfizer's pipeline.
                </p>
            </div>
        </div>

        <!-- Valuation Section -->
        <div class="tab-container" style="margin-top: 24px;">
            <div style="padding: 24px;">
                <div class="section-title">4.3 Valuation & Exit Modeling</div>
                
                <div class="data-card">
                    <h4 class="font-semibold mb-2">Risk-Adjusted NPV Analysis</h4>
                    
                    <p class="detail-text">
                        <strong>Probability of Success (PoS):</strong> DV is through Phase 3 in its initial indication, so for China it's already approved (100% PoS realized there). For US/EU, PoS is high for at least some niche approval, perhaps ~70%. However, if aiming for a broader label (HER2-low), PoS is lower until more trials. Let's assume ~50% chance of a meaningful US/EU approval.
                    </p>

                    <p class="detail-text mt-2">
                        <strong>Base Case Scenario:</strong>
                        <br>• DV gets approved in US/EU for 3L HER2+ and post-T-DXd HER2-low by ~2026
                        <br>• Peak global sales ~$1.2B in 2030
                        <br>• Using 10% discount, NPV of cash flows ~$1.5B (for ex-China) and add China cash flows NPV $0.5B, total $2.0B
                        <br>• Multiply by PoS (50%) = $1.0B rNPV to RemeGen
                    </p>

                    <p class="detail-text mt-2">
                        <strong>Upside Case:</strong>
                        <br>• DV gets broader use (2L HER2-low, some first-line combos), peak sales $2B
                        <br>• NPV maybe $3B, PoS 30% (since it requires new trials success) => ~$0.9B rNPV
                    </p>

                    <p class="detail-text mt-2">
                        <strong>Downside Case:</strong>
                        <br>• Global approval is very limited or delayed – peak sales $300M
                        <br>• NPV ~$400M, PoS perhaps 20% => ~$80M rNPV
                    </p>
                </div>

                <div class="metric-grid mt-4">
                    <div class="metric-card">
                        <div class="metric-label">Base Case rNPV</div>
                        <div class="metric-value">$1.0B</div>
                        <div class="metric-detail">50% PoS</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">China Peak Sales</div>
                        <div class="metric-value">$450M</div>
                        <div class="metric-detail">RMB3.1B analyst est.</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Global Peak Sales</div>
                        <div class="metric-value">$1.0-1.2B</div>
                        <div class="metric-detail">Base case</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Expected IRR</div>
                        <div class="metric-value">15-20%</div>
                        <div class="metric-detail">For Blackstone</div>
                    </div>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-2">Exit Strategy Options</h4>
                    
                    <p class="detail-text">
                        <strong>IPO/Public Market:</strong> RemeGen is already public. Pfizer is obviously public. No need for IPO. However, an exit for an investor like Blackstone could be selling their RemeGen stake in the open market or selling the royalty stream to another party once DV is de-risked.
                    </p>

                    <p class="detail-text">
                        <strong>Acquisition Potential:</strong> Pfizer could consider acquiring RemeGen or at least its remaining rights if DV becomes extremely important. Or another Big Pharma might target RemeGen for Telitacicept and get DV's China rights as bonus.
                    </p>

                    <p class="detail-text">
                        <strong>Royalty Monetization:</strong> RemeGen's royalty is a steady cash flow. Blackstone could structure to get those flows. For example, HealthCare Royalty Partners did a deal with ADC Therapeutics for Zynlonta sales. Similarly, Blackstone could do a capped royalty deal on DV.
                    </p>

                    <p class="detail-text">
                        <strong>Milestone Financing:</strong> Another strategy is to finance RemeGen's pipeline by advancing cash in exchange for part of Pfizer's milestone payments later. For instance, Blackstone might pay RemeGen $50M now, and when Pfizer pays the $100M FDA approval milestone, Blackstone takes $80M of it.
                    </p>
                </div>
            </div>
        </div>

        <!-- Operational & Legal Section -->
        <div class="tab-container" style="margin-top: 24px;">
            <div style="padding: 24px;">
                <div class="section-title">5. Operational & Legal Diligence</div>
                
                <div class="subsection-title">5.1 Manufacturing & CMC</div>
                
                <div class="highlight-box">
                    <h4 class="font-semibold mb-2">Manufacturing Overview</h4>
                    <p class="detail-text">
                        Disitamab vedotin is a complex biologic-plus-chemical product. RemeGen built manufacturing capabilities in Yantai, China, including an ADC conjugation facility. They have been supplying the Chinese market since 2021 for gastric and bladder indications, so commercial-scale manufacturing is already in place for China.
                    </p>
                </div>

                <div class="metric-grid">
                    <div class="metric-card">
                        <div class="metric-label">Production Capacity</div>
                        <div class="metric-value">90,000L</div>
                        <div class="metric-detail">Biologics capacity</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">DAR Consistency</div>
                        <div class="metric-value">~4</div>
                        <div class="metric-detail">Drug-antibody ratio</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Shelf Life</div>
                        <div class="metric-value">24 months</div>
                        <div class="metric-detail">Refrigerated storage</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Hospital Coverage</div>
                        <div class="metric-value">374</div>
                        <div class="metric-detail">In China</div>
                    </div>
                </div>

                <p class="detail-text mt-4">
                    <strong>Global Manufacturing Strategy:</strong> For global supply, Pfizer/Seagen will either: (1) Use RemeGen's facility under supervision (if it passes FDA inspection), or (2) Tech-transfer the production to one of Seagen's partner CMOs or their own manufacturing plant in the US.
                </p>

                <p class="detail-text">
                    <strong>Supply Chain Components:</strong> The payload supply (MMAE) might come from a specific manufacturer – possibly a Seagen affiliate, since MMAE is proprietary. The antibody gene could be expressed in CHO cells; RemeGen likely has a cell bank.
                </p>

                <p class="detail-text">
                    <strong>Quality Systems:</strong> RemeGen's Chief Medical Officer, He Ruyi, served at both US FDA and China NMPA for ~20 years, which means internally they have strong compliance expertise. That reduces risk of missteps in regulatory filings or trial conduct.
                </p>

                <div class="subsection-title">5.2 Legal & Compliance Status</div>

                <div class="data-card">
                    <h4 class="font-semibold mb-2">Regulatory Compliance</h4>
                    <p class="detail-text">
                        RemeGen and DV have not had any known regulatory compliance issues publicly. RemeGen's facilities presumably underwent Chinese inspections for GMP – no warning letters known. In the U.S., since DV hasn't been filed, there's no FDA compliance history for it yet.
                    </p>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-2">Litigation Status</h4>
                    <ul class="space-y-2">
                        <li>• <strong>IP Litigation:</strong> None ongoing, low risk after licensing</li>
                        <li>• <strong>Product Liability:</strong> DV hasn't had safety issues causing lawsuits (no deaths, etc.)</li>
                        <li>• <strong>Securities Litigation:</strong> No current securities lawsuits known</li>
                        <li>• <strong>Patent Challenges:</strong> No known patent litigations or opposition proceedings filed against DV</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-2">Partnership Obligations</h4>
                    <p class="detail-text">
                        The Seagen license: Since Seagen licensed from RemeGen, RemeGen doesn't owe milestones, it receives them. RemeGen will fund and operationalize trials attributable to its territory. So RemeGen bears cost for China/Asia parts of global trials.
                    </p>
                </div>
            </div>
        </div>

        <!-- Management & Team Section -->
        <div class="tab-container" style="margin-top: 24px;">
            <div style="padding: 24px;">
                <div class="section-title">6. Management & Team Execution</div>
                
                <div class="data-card">
                    <h4 class="font-semibold mb-2">Leadership Team</h4>
                    
                    <p class="detail-text">
                        <strong>Dr. Jianmin Fang (CEO & Co-founder):</strong> A PhD biologist trained in Canada, with >20 years of biopharma R&D experience. He's the scientific visionary behind DV (inventor listed on its patents). Having a scientist-CEO can be great for innovation.
                    </p>

                    <p class="detail-text">
                        <strong>Mr. Weidong Wang (Chairman/Co-founder):</strong> He previously built a successful pharma (Rongchang) in China, suggesting business acumen and government relations. Likely instrumental in NRDL negotiations.
                    </p>

                    <p class="detail-text">
                        <strong>Dr. Ruyi He (CMO):</strong> Critical hire; ex-FDA medical officer and ex-CDE (China's FDA). His regulatory expertise likely helped secure Breakthrough designations and navigate trial design issues.
                    </p>

                    <p class="detail-text">
                        <strong>Dr. Daotian Fu (President):</strong> With 28 years in US biotech leadership, he likely oversees global collaborations and perhaps manufacturing. This international experience on the team is a green flag.
                    </p>
                </div>

                <div class="metric-grid mt-4">
                    <div class="metric-card">
                        <div class="metric-label">Team Size</div>
                        <div class="metric-value">180</div>
                        <div class="metric-detail">Oncology reps</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Hospital Coverage</div>
                        <div class="metric-value">374</div>
                        <div class="metric-detail">In China</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Approved Indications</div>
                        <div class="metric-value">3</div>
                        <div class="metric-detail">In China</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Pipeline Studies</div>
                        <div class="metric-value">20+</div>
                        <div class="metric-detail">Global trials</div>
                    </div>
                </div>

                <p class="detail-text mt-4">
                    <strong>Execution Track Record:</strong> So far, RemeGen's team has successfully brought two drugs from Phase 1 to approval in China (in multiple indications), managed a major global licensing deal (with Seagen) and partnership (with Lilly), and achieved reimbursement listings quickly (NRDL within the same year of approval for DV's first indications).
                </p>

                <p class="detail-text">
                    <strong>Team Risks:</strong> Rapid expansion can stretch management bandwidth. Dr. Fang is key; if anything happened to him, would the science drive continue? They do have other scientific leaders, but losing a founder often impacts investor confidence.
                </p>
            </div>
        </div>

        <!-- Complete Trial Analysis Section -->
        <div class="tab-container" style="margin-top: 24px;">
            <div style="padding: 24px;">
                <div class="section-title">7. Complete Trial Portfolio Analysis</div>
                
                <table class="trial-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Key Results</th>
                            <th>Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Phase 1/1b China</strong></td>
                            <td>1/1b</td>
                            <td>136</td>
                            <td>HER2+ and HER2-low MBC</td>
                            <td>ORR 42.9% (HER2+), 33.3% (HER2-low); mPFS 5.7mo/5.1mo</td>
                            <td>Completed</td>
                        </tr>
                        <tr>
                            <td><strong>RC48-C006 (NCT03500380)</strong></td>
                            <td>3</td>
                            <td>104</td>
                            <td>HER2+ MBC with liver mets</td>
                            <td>PFS 9.9 vs 4.9mo, HR 0.56, p=0.0143</td>
                            <td>Approved China</td>
                        </tr>
                        <tr>
                            <td>Phase 2 "Umbrella" China</td>
                            <td>2</td>
                            <td>~120</td>
                            <td>Mixed HER2 status MBC</td>
                            <td>Overall ORR 38.3%, mPFS 5.7mo</td>
                            <td>Completed</td>
                        </tr>
                        <tr>
                            <td>RC48 + Toripalimab (UC)</td>
                            <td>1b/2</td>
                            <td>43</td>
                            <td>Metastatic urothelial</td>
                            <td>ORR ~75%, mOS 33mo</td>
                            <td>Ongoing</td>
                        </tr>
                        <tr>
                            <td>RC48G001 (Global UC)</td>
                            <td>2</td>
                            <td>TBD</td>
                            <td>HER2+ urothelial</td>
                            <td>Includes US cohorts</td>
                            <td>Recruiting</td>
                        </tr>
                        <tr>
                            <td>HER2-low HR+ Combo</td>
                            <td>2</td>
                            <td>Planned</td>
                            <td>HER2-low HR+ MBC</td>
                            <td>DV + endocrine therapy</td>
                            <td>Planning</td>
                        </tr>
                    </tbody>
                </table>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-2">Additional Indications in China</h4>
                    <ul class="space-y-2">
                        <li>• <strong>Gastric Cancer:</strong> First approval (2021), HER2-positive locally advanced or metastatic</li>
                        <li>• <strong>Urothelial Cancer:</strong> Second approval (2022), HER2-positive locally advanced or metastatic</li>
                        <li>• <strong>Breast Cancer:</strong> Third approval (2025), HER2+ with liver metastases</li>
                        <li>• <strong>Cervical Cancer:</strong> Phase 2 data reported, potential fourth indication</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Investment Summary Section -->
        <div class="tab-container" style="margin-top: 24px;">
            <div style="padding: 24px;">
                <div class="section-title">Investment Committee Summary</div>
                
                <div class="highlight-box">
                    <h3 class="text-xl font-bold mb-4 text-gray-900">Executive Investment Thesis</h3>
                    <p class="detail-text">
                        Disitamab vedotin represents a compelling late-stage oncology investment with proven clinical benefit in an unmet population. As the first ADC globally approved specifically for HER2+ breast cancer with liver metastases, it addresses a clear need. The partnership with Pfizer mitigates regulatory and commercial execution risks ex-China, while RemeGen's strong execution in China validates the commercial model.
                    </p>
                </div>

                <div class="metric-grid mt-6">
                    <div class="metric-card">
                        <div class="metric-label">Clinical Risk</div>
                        <div class="metric-value" style="color: #28a745;">✓ Low</div>
                        <div class="metric-detail">Phase 3 met primary, China approved</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Regulatory Risk</div>
                        <div class="metric-value" style="color: #ffc107;">⚠ Medium</div>
                        <div class="metric-detail">Comparator issue for FDA/EMA</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Commercial Risk</div>
                        <div class="metric-value" style="color: #ffc107;">⚠ Medium</div>
                        <div class="metric-detail">Competition from T-DXd</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Financial Upside</div>
                        <div class="metric-value" style="color: #28a745;">✓ High</div>
                        <div class="metric-detail">$1-2B peak sales potential</div>
                    </div>
                </div>

                <div class="data-card mt-6">
                    <h4 class="font-semibold mb-3">Key Investment Strengths</h4>
                    <ul class="space-y-2">
                        <li>✓ <strong>No ILD Signal:</strong> Key safety differentiator vs T-DXd (10-15% ILD rate)</li>
                        <li>✓ <strong>Proven Efficacy:</strong> 44% risk reduction (HR 0.56) in Phase 3, doubled PFS to 9.9 months</li>
                        <li>✓ <strong>HER2-low Activity:</strong> ORR ~30-33% in HER2-low, expanding addressable market</li>
                        <li>✓ <strong>China Success:</strong> Already approved for 3 indications, NRDL listed, rapid uptake</li>
                        <li>✓ <strong>Strong IP:</strong> Protection to 2034-2039 with composition-of-matter patents</li>
                        <li>✓ <strong>Pfizer Partnership:</strong> $200M upfront + $2.4B milestones validates asset</li>
                        <li>✓ <strong>Manufacturing Ready:</strong> Commercial-scale production already operational</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Key Investment Risks</h4>
                    <ul class="space-y-2">
                        <li>⚠ <strong>Outdated Comparator:</strong> Phase 3 used lapatinib+cape, not current SOC</li>
                        <li>⚠ <strong>T-DXd Competition:</strong> Superior efficacy in HER2+ and HER2-low</li>
                        <li>⚠ <strong>Small Trial Size:</strong> N=104 in pivotal, all Chinese patients</li>
                        <li>⚠ <strong>Neuropathy Risk:</strong> ~45% any grade, 6% Grade 3+ (MMAE effect)</li>
                        <li>⚠ <strong>Patent Expiry:</strong> Base patents expire 2034, relatively short window</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Financial Projections</h4>
                    <table class="trial-table">
                        <thead>
                            <tr>
                                <th>Scenario</th>
                                <th>Peak Sales</th>
                                <th>Probability</th>
                                <th>rNPV</th>
                                <th>IRR</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Conservative</td>
                                <td>$800M</td>
                                <td>40%</td>
                                <td>$0.8B</td>
                                <td>15-18%</td>
                            </tr>
                            <tr style="background: #f0f7f6;">
                                <td><strong>Base Case</strong></td>
                                <td><strong>$1.2B</strong></td>
                                <td><strong>50%</strong></td>
                                <td><strong>$1.0B</strong></td>
                                <td><strong>18-22%</strong></td>
                            </tr>
                            <tr>
                                <td>Bull Case</td>
                                <td>$2.0B</td>
                                <td>30%</td>
                                <td>$0.9B</td>
                                <td>25-30%</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="highlight-box mt-6">
                    <h4 class="font-semibold mb-2">Investment Recommendation</h4>
                    <p class="detail-text">
                        <strong>Rating: BUY with structured approach</strong>
                        <br><br>
                        Disitamab vedotin offers compelling risk-adjusted returns given its proven efficacy, differentiated safety profile (no ILD), and strong China execution. The Pfizer partnership de-risks global development while RemeGen's ~$6.5B valuation provides multiple entry points. Recommend investment via:
                        <br><br>
                        1. <strong>Royalty financing:</strong> Purchase portion of ex-China royalty stream (10-15% royalties on $1B+ sales)
                        <br>2. <strong>Milestone monetization:</strong> Advance capital against future Pfizer milestone payments
                        <br>3. <strong>Equity investment:</strong> Direct stake in RemeGen given multiple value drivers (DV + Telitacicept)
                        <br><br>
                        Key catalysts include FDA IND filing (2025-26), potential breakthrough designation for HER2-low, and continued China revenue ramp. Monitor T-DXd real-world ILD rates and any new HER2 ADC entrants. Exit likely via royalty sale or RemeGen appreciation as DV reaches peak sales (~2030).
                    </p>
                </div>

                <div class="reference-list">
                    Data compiled from: SABCS 2024 Presentations | RemeGen Corporate Filings | Seagen SEC Documents | 
                    PubMed PMID: 38940019 | ClinicalTrials.gov | ADC Review | Annals of Oncology | PRNewswire | 
                    BOCOM Securities Analysis | Investing.com | FiercePharma | Company Investor Relations
                </div>
            </div>
        </div>
    </div>
    <!-- Operational & Legal Tab -->
<div id="operational" class="tab-content">
    <div class="section-title">5. Operational & Legal Diligence</div>
    
    <!-- Manufacturing -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>5.1 Manufacturing & CMC (Chemistry, Manufacturing, Controls)</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Manufacturing Scale & Readiness</h4>
                <p class="detail-text">
                    Disitamab vedotin is a complex biologic-plus-chemical product. RemeGen built manufacturing capabilities in Yantai, China, including an ADC conjugation facility. They have been supplying the Chinese market since 2021 for gastric and bladder indications, so commercial-scale manufacturing is already in place for China. RemeGen in filings noted a 90,000L biologics production capacity (for RC18, RC48 etc.) – an impressive scale.
                </p>
            </div>

            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Production Capacity</div>
                    <div class="metric-value">90,000L</div>
                    <div class="metric-detail">Biologics capacity</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">DAR Consistency</div>
                    <div class="metric-value">~4</div>
                    <div class="metric-detail">MMAE per antibody</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Shelf Life</div>
                    <div class="metric-value">24 months</div>
                    <div class="metric-detail">Refrigerated storage</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Batch Consistency</div>
                    <div class="metric-value">Validated</div>
                    <div class="metric-detail">No recalls reported</div>
                </div>
            </div>

            <p class="detail-text mt-4">
                <strong>CMC Status:</strong> Key CMC elements for ADCs include the antibody production, the linker-payload synthesis, and the conjugation step (which yields a specific Drug-Antibody Ratio, DAR). DV uses MMAE, which Seagen produces or sources. The antibody is presumably produced in mammalian cell culture. For DV, batch size likely in the hundreds of liters can produce ample supply. 
            </p>

            <p class="detail-text">
                <strong>Global Manufacturing Strategy:</strong> According to the license deal, Seagen leads global development and RemeGen operationalizes trials in its territory. For global supply, Pfizer/Seagen will either: Use RemeGen's facility under supervision (if it passes FDA inspection – possible given modern Chinese facilities can meet standards), or tech-transfer the production to one of Seagen's partner CMOs or their own manufacturing plant in the US.
            </p>

            <p class="detail-text">
                <strong>Supply Chain:</strong> The payload supply (MMAE) might come from a specific manufacturer – possibly a Seagen affiliate. There's a dependency risk if only one plant makes MMAE, but Seagen likely has contingencies or stockpiles. Raw material risks include the linker (valine-citrulline-PABC) and MMAE are specialized.
            </p>
        </div>
    </div>

    <!-- Legal & Compliance -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>5.2 Legal, Compliance, and Other Operational Risks</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h4 class="font-semibold mb-2">Regulatory Compliance</h4>
                <p class="detail-text">
                    RemeGen and DV have not had any known regulatory compliance issues publicly. RemeGen's facilities presumably underwent Chinese inspections for GMP – no warning letters known. RemeGen's Chief Medical Officer, He Ruyi, served at both US FDA and China NMPA for ~20 years, which means internally they have strong compliance expertise.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Litigation Status</h4>
                <ul class="space-y-2">
                    <li>• <strong>IP Litigation:</strong> None ongoing. No known patent litigations or opposition proceedings have been filed against DV. RemeGen's collaboration structure has likely deterred competitors from IP challenges.</li>
                    <li>• <strong>Product Liability:</strong> DV hasn't had safety issues causing lawsuits. No treatment-related deaths across studies.</li>
                    <li>• <strong>Securities/Investor Litigation:</strong> RemeGen being public means any missteps could cause class actions. Given DV's success, that's not current. No current securities lawsuits known.</li>
                    <li>• <strong>Compliance (FDA/EMA):</strong> As DV moves to global, ensure all data (especially Chinese trial data) is GCP-compliant and auditable.</li>
                </ul>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Partner Obligations</h4>
                <p class="detail-text">
                    <strong>The Seagen License:</strong> Since Seagen licensed from RemeGen, RemeGen doesn't owe milestones, it receives them. However, RemeGen will fund and operationalize trials attributable to its territory. So RemeGen bears cost for China/Asia parts of global trials. No signs of partnership strain.
                </p>
                <p class="detail-text mt-2">
                    <strong>Other Partnerships:</strong> RemeGen has other partnerships (e.g., telitacicept with Lilly for ex-China). No conflict with DV. DV uses Seagen IP, which is confined to DV.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Operational Red Flags & Mitigations</h4>
                <div class="risk-item">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Manufacturing scale-up for global demand:</strong> Might encounter hiccups or FDA compliance issues. Mitigation: Pfizer's CMC experts should lead global manufacturing strategy.
                    </div>
                </div>
                <div class="risk-item">
                    <div class="risk-indicator risk-low"></div>
                    <div>
                        <strong>Single-source dependencies:</strong> E.g., sole supplier of MMAE. Mitigation: Seagen likely already has backup suppliers in place.
                    </div>
                </div>
                <div class="risk-item">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Geopolitical risk:</strong> U.S.-China tensions could impair data sharing. Mitigation: Include U.S. sites in future DV trials to ensure FDA comfort.
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>

<!-- Management & Team Tab -->
<div id="management" class="tab-content">
    <div class="section-title">6. Management & Team Execution</div>
    
    <!-- Leadership Experience -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>6.1 Leadership Experience</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="data-card">
                <h4 class="font-semibold mb-2">RemeGen Leadership Team</h4>
                
                <p class="detail-text">
                    <strong>Dr. Jianmin Fang (CEO & Co-founder):</strong> A PhD biologist trained in Canada, with >20 years of biopharma R&D experience. He's the scientific visionary behind DV (inventor listed on its patents). Having a scientist-CEO can be great for innovation but one must ensure he's supported by strong commercial operators.
                </p>

                <p class="detail-text">
                    <strong>Mr. Weidong Wang (Chairman/Co-founder):</strong> He previously built a successful pharma (Rongchang) in China, suggesting business acumen and government relations. Likely instrumental in NRDL negotiations.
                </p>

                <p class="detail-text">
                    <strong>Dr. Ruyi He (CMO):</strong> Critical hire; ex-FDA medical officer and ex-CDE (China's FDA). His regulatory expertise likely helped secure Breakthrough designations and navigate trial design issues. He ensures clinical development rigor and compliance.
                </p>

                <p class="detail-text">
                    <strong>Dr. Daotian Fu (President):</strong> With 28 years in US biotech leadership. He likely oversees global collaborations and perhaps manufacturing. This international experience on the team is a green flag – he understands Western quality and business practices.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Founded</div>
                    <div class="metric-value">2008</div>
                    <div class="metric-detail">17 years operating</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Products Approved</div>
                    <div class="metric-value">2</div>
                    <div class="metric-detail">Multiple indications</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Partnerships</div>
                    <div class="metric-value">3 Major</div>
                    <div class="metric-detail">Pfizer, Lilly, etc.</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Employee Count</div>
                    <div class="metric-value">~1,000+</div>
                    <div class="metric-detail">Growing rapidly</div>
                </div>
            </div>
        </div>
    </div>

    <!-- Team Execution -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>6.2 Team Cohesion & Execution Track Record</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <p class="detail-text">
                <strong>Execution Track Record:</strong> So far, RemeGen's team has successfully brought two drugs from Phase 1 to approval in China (in multiple indications), managed a major global licensing deal (with Seagen) and partnership (with Lilly), scaled up a commercial infrastructure and achieved reimbursement listings quickly (NRDL within the same year of approval), and maintained pipeline progression (presented 15 studies of DV at ASCO 2024).
            </p>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Commercial Team Strength</h4>
                <p class="detail-text">
                    They assembled large salesforces for RC18 and RC48 in China – 180 oncology reps covering 374 hospitals. That's operational heavy-lifting to cover hundreds of hospitals. It seems they executed well, given the sales jump and broad hospital coverage.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Potential Team Risks</h4>
                <ul class="space-y-2">
                    <li>• <strong>Rapid expansion:</strong> Can stretch management bandwidth – concurrently handling regulatory filings, new trials, and product launches</li>
                    <li>• <strong>Succession planning:</strong> Dr. Fang is key; losing a founder often impacts investor confidence</li>
                    <li>• <strong>Integration with Pfizer:</strong> Communication delays or strategic disagreements possible</li>
                    <li>• <strong>Global expansion:</strong> Team must effectively influence Pfizer to push DV's best chances</li>
                </ul>
            </div>
        </div>
    </div>
</div>

<!-- Safety & Toxicology Tab -->
<div id="safety" class="tab-content">
    <div class="section-title">7. Comprehensive Safety & Toxicology Profile</div>
    
    <!-- Phase 1/2 Safety -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7.1 Phase 1/2 Safety Data</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Dose Escalation & Expansion Results</h4>
                <p class="detail-text">
                    No dose-limiting toxicities observed up to 2.5 mg/kg. Maximum tolerated dose not formally reached. Recommended Phase 2/3 dose: 2.0 mg/kg Q2W based on optimal balance of efficacy and tolerability.
                </p>
            </div>

            <table class="ae-table">
                <thead>
                    <tr>
                        <th>Adverse Event</th>
                        <th>All Grades (%)</th>
                        <th>Grade 3 (%)</th>
                        <th>Grade 4 (%)</th>
                        <th>Led to Discontinuation</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Peripheral neuropathy</td>
                        <td>45-50%</td>
                        <td>5.9%</td>
                        <td>0.7%</td>
                        <td><2%</td>
                    </tr>
                    <tr>
                        <td>Neutropenia</td>
                        <td>50-55%</td>
                        <td>17-19%</td>
                        <td>Rare</td>
                        <td>Managed with G-CSF</td>
                    </tr>
                    <tr>
                        <td>AST elevation</td>
                        <td>46%</td>
                        <td><5%</td>
                        <td>0</td>
                        <td>No</td>
                    </tr>
                    <tr>
                        <td>ALT elevation</td>
                        <td>42%</td>
                        <td><5%</td>
                        <td>0</td>
                        <td>No</td>
                    </tr>
                    <tr>
                        <td>Nausea</td>
                        <td>30%</td>
                        <td>One patient</td>
                        <td>0</td>
                        <td>No</td>
                    </tr>
                    <tr>
                        <td>Fatigue</td>
                        <td>25%</td>
                        <td>Rare</td>
                        <td>0</td>
                        <td>No</td>
                    </tr>
                </tbody>
            </table>

            <p class="detail-text mt-4">
                <strong>Key Safety Findings:</strong> Only 1 patient (<2%) discontinued due to TRAE. Only 1 patient required dose reduction (Grade 3 nausea). No Grade 4 treatment-related AEs except rare neutropenia. No treatment-related deaths. Febrile neutropenia was uncommon (<5%).
            </p>
        </div>
    </div>

    <!-- Comparative Safety -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7.2 Comparative Safety vs Other HER2 ADCs</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Key Safety Differentiator: No ILD Signal</h4>
                <p class="detail-text">
                    Disitamab vedotin has not shown the interstitial lung disease (ILD) signal that is associated with trastuzumab deruxtecan (T-DXd). In all Chinese trials of DV, no ILD or pneumonitis of grade ≥3 was reported. This is a major differentiator.
                </p>
            </div>

            <table class="trial-table">
                <thead>
                    <tr>
                        <th>Safety Parameter</th>
                        <th>Disitamab Vedotin</th>
                        <th>T-DXd (Enhertu)</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>ILD/Pneumonitis</td>
                        <td>0%</td>
                        <td>10-15% (0.8% fatal)</td>
                        <td>Major safety advantage</td>
                    </tr>
                    <tr>
                        <td>Peripheral neuropathy</td>
                        <td>45% (6% G3)</td>
                        <td><5%</td>
                        <td>MMAE class effect</td>
                    </tr>
                    <tr>
                        <td>Neutropenia G3+</td>
                        <td>17-19%</td>
                        <td>~20%</td>
                        <td>Comparable</td>
                    </tr>
                    <tr>
                        <td>Nausea</td>
                        <td>30%</td>
                        <td>73%</td>
                        <td>Better GI tolerability</td>
                    </tr>
                    <tr>
                        <td>Alopecia</td>
                        <td>Minimal</td>
                        <td>~40%</td>
                        <td>QoL advantage</td>
                    </tr>
                    <tr>
                        <td>Cardiotoxicity</td>
                        <td>Not reported</td>
                        <td>Low</td>
                        <td>No signal</td>
                    </tr>
                </tbody>
            </table>

            <p class="detail-text mt-4">
                <strong>Clinical Implications:</strong> The lack of ILD makes DV a safer alternative for patients with lung comorbidities or those who cannot risk pulmonary toxicity. The neuropathy is manageable with dose modifications and rarely leads to discontinuation.
            </p>
        </div>
    </div>

    <!-- Special Populations -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7.3 Special Populations & Drug Interactions</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="data-card">
                <h4 class="font-semibold mb-2">Liver Metastases Population</h4>
                <p class="detail-text">
                    Despite patients having liver impairment risk (due to metastases), DV did not exhibit unexpected hepatotoxicity beyond mild transaminase rises. No cases of severe drug-induced liver injury have been reported. Grade ≥3 gamma-GT elevation occurred in 13.2%.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Combination Safety</h4>
                <p class="detail-text">
                    <strong>With Immunotherapy:</strong> DV + anti-PD-1 (toripalimab) in urothelial cancer showed no significant worsening of toxicity. Grade ≥3 TRAEs ~36.5% in combination.
                </p>
                <p class="detail-text mt-2">
                    <strong>With Targeted Therapy:</strong> Combinations with CDK4/6 inhibitors or anti-VEGF agents are being explored. Preliminary data suggest manageable safety profiles.
                </p>
            </div>
        </div>
    </div>
</div>

<!-- Complete Trial Analysis Tab -->
<div id="trials" class="tab-content">
    <div class="section-title">8. Complete Trial Portfolio Analysis</div>
    
    <div class="subsection-title">Comprehensive Clinical Development Program</div>
    
    <table class="trial-table">
        <thead>
            <tr>
                <th>Trial</th>
                <th>Phase</th>
                <th>N</th>
                <th>Population</th>
                <th>Design</th>
                <th>Key Results</th>
                <th>Status</th>
            </tr>
        </thead>
        <tbody>
            <tr style="background: #f0f7f6;">
                <td><strong>RC48-C006</strong><br>(NCT03500380)</td>
                <td><strong>3</strong></td>
                <td><strong>104</strong></td>
                <td><strong>HER2+ MBC with liver mets</strong></td>
                <td>DV vs lapatinib+cape</td>
                <td><strong>PFS 9.9 vs 4.9mo<br>HR 0.56, p=0.0143</strong></td>
                <td><strong>APPROVED CHINA</strong></td>
            </tr>
            <tr>
                <td>Phase 1/1b China</td>
                <td>1/1b</td>
                <td>136</td>
                <td>HER2+ and HER2-low MBC</td>
                <td>Dose escalation/expansion</td>
                <td>ORR 42.9% (HER2+)<br>33.3% (HER2-low)</td>
                <td>Completed</td>
            </tr>
            <tr>
                <td>Phase 2 Umbrella</td>
                <td>2</td>
                <td>~120</td>
                <td>Mixed HER2 status</td>
                <td>Single-arm observational</td>
                <td>ORR 38.3%, mPFS 5.7mo</td>
                <td>Completed</td>
            </tr>
            <tr>
                <td>RC48 + Toripalimab</td>
                <td>1b/2</td>
                <td>43</td>
                <td>Metastatic UC</td>
                <td>Combination</td>
                <td>ORR 75%, mOS 33mo</td>
                <td>Ongoing</td>
            </tr>
            <tr>
                <td>RC48G001</td>
                <td>2</td>
                <td>TBD</td>
                <td>HER2+ UC (global)</td>
                <td>Includes US cohorts</td>
                <td>Enrolling</td>
                <td>Recruiting</td>
            </tr>
            <tr>
                <td>HER2-low Combo</td>
                <td>2</td>
                <td>Planned</td>
                <td>HER2-low HR+ MBC</td>
                <td>DV + endocrine</td>
                <td>Planning</td>
                <td>Planning</td>
            </tr>
        </tbody>
    </table>

    <div class="data-card mt-4">
        <h4 class="font-semibold mb-2">Multi-Indication Development in China</h4>
        <table class="trial-table">
            <thead>
                <tr>
                    <th>Indication</th>
                    <th>Approval Status</th>
                    <th>Key Data</th>
                    <th>NRDL Status</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Gastric Cancer</strong></td>
                    <td>Approved 2021</td>
                    <td>HER2+ locally advanced/metastatic</td>
                    <td>Listed</td>
                </tr>
                <tr>
                    <td><strong>Urothelial Cancer</strong></td>
                    <td>Approved 2022</td>
                    <td>HER2+ locally advanced/metastatic</td>
                    <td>Listed</td>
                </tr>
                <tr>
                    <td><strong>Breast Cancer</strong></td>
                    <td>Approved May 2025</td>
                    <td>HER2+ with liver metastases</td>
                    <td>Pending</td>
                </tr>
                <tr>
                    <td>Cervical Cancer</td>
                    <td>Phase 2</td>
                    <td>Data reported</td>
                    <td>-</td>
                </tr>
                <tr>
                    <td>Lung Cancer</td>
                    <td>Phase 2</td>
                    <td>HER2-mutant NSCLC</td>
                    <td>-</td>
                </tr>
            </tbody>
        </table>
    </div>

    <div class="subsection-title mt-4">Future Development Strategy</div>
    
    <div class="data-card">
        <h4 class="font-semibold mb-2">Pfizer Global Development Plans</h4>
        <ul class="space-y-2">
            <li>• <strong>HER2-low breast cancer:</strong> Potential Phase 3 vs physician's choice in post-T-DXd setting</li>
            <li>• <strong>Third-line HER2+ MBC:</strong> Single-arm study in Western patients post-T-DXd</li>
            <li>• <strong>Combination strategies:</strong> DV + checkpoint inhibitors, DV + CDK4/6i for HR+</li>
            <li>• <strong>Earlier lines:</strong> First-line combinations if differentiation established</li>
            <li>• <strong>Companion diagnostic:</strong> No new test needed, standard HER2 IHC/FISH sufficient</li>
        </ul>
    </div>

    <div class="reference-list">
        Trial data compiled from: ClinicalTrials.gov | SABCS 2024 | ASCO 2024 | RemeGen Corporate Presentations | 
        PubMed | Annals of Oncology | OncoLive | ADC Review
    </div>
</div>

    <script>
        // ============================================
// COMPLETE SCRIPT FOR DISITAMAB VEDOTIN REPORT
// ============================================

// Tab switching function
function showTab(tabName) {
    document.querySelectorAll('.tab-content').forEach(tab => {
        tab.classList.remove('active');
    });
    
    document.querySelectorAll('.tab-btn').forEach(btn => {
        btn.classList.remove('active');
    });
    
    const targetTab = document.getElementById(tabName);
    if (targetTab) {
        targetTab.classList.add('active');
    }
    
    if (event && event.target) {
        event.target.classList.add('active');
    }
}

// Toggle expandable sections
function toggleSection(header) {
    const content = header.nextElementSibling;
    const arrow = header.querySelector('span:last-child');
    
    if (content.classList.contains('active')) {
        content.classList.remove('active');
        arrow.textContent = '▶';
    } else {
        content.classList.add('active');
        arrow.textContent = '▼';
    }
}

// Initialize all charts and functionality on page load
window.addEventListener('DOMContentLoaded', function() {
    
    // ==========================================
    // PFS COMPARISON CHART (Phase 3 Results)
    // ==========================================
    const pfsCtx = document.getElementById('pfsChart');
    if (pfsCtx) {
        new Chart(pfsCtx.getContext('2d'), {
            type: 'bar',
            data: {
                labels: ['DV (RC48) Phase 3', 'Lapatinib+Cape', 'HER2+ Phase 1/2', 'HER2-low Phase 1/2'],
                datasets: [{
                    label: 'Median PFS (months)',
                    data: [9.9, 4.9, 5.7, 5.1],
                    backgroundColor: ['#0a6b5e', '#e3f2f0', '#0a6b5e', '#e3f2f0'],
                    borderColor: '#0a6b5e',
                    borderWidth: 1
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'RC48-C006: Progression-Free Survival Results',
                        font: {
                            size: 16
                        }
                    },
                    legend: {
                        display: false
                    },
                    tooltip: {
                        callbacks: {
                            label: function(context) {
                                return 'Median PFS: ' + context.parsed.y + ' months';
                            }
                        }
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        max: 12,
                        title: {
                            display: true,
                            text: 'Months'
                        }
                    },
                    x: {
                        ticks: {
                            maxRotation: 45,
                            minRotation: 45
                        }
                    }
                }
            }
        });
    }

    // ==========================================
    // SAFETY COMPARISON CHART
    // ==========================================
    const safetyCtx = document.getElementById('safetyComparisonChart');
    if (safetyCtx) {
        new Chart(safetyCtx.getContext('2d'), {
            type: 'bar',
            data: {
                labels: ['AST Elevation', 'ALT Elevation', 'Neutropenia', 'Peripheral Neuropathy', 'Nausea', 'Fatigue', 'ILD/Pneumonitis'],
                datasets: [{
                    label: 'Disitamab Vedotin (%)',
                    data: [46, 42, 50, 45, 30, 25, 0],
                    backgroundColor: '#0a6b5e'
                }, {
                    label: 'T-DXd/Enhertu (%)',
                    data: [15, 15, 20, 5, 35, 30, 12],
                    backgroundColor: '#dc3545'
                }]
            },
            options: {
                 indexAxis: 'y',
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'Adverse Event Comparison: RC48 vs T-DXd'
                    },
                    legend: {
                        display: true,
                        position: 'top'
                    }
                },
                scales: {
                    x: {
                        beginAtZero: true,
                        max: 60,
                        title: {
                            display: true,
                            text: 'Incidence (%)'
                        }
                    }
                }
            }
        });
    }

    // ==========================================
    // SALES PROJECTION CHART
    // ==========================================
    const salesCtx = document.getElementById('salesProjectionChart');
    if (salesCtx) {
        new Chart(salesCtx.getContext('2d'), {
            type: 'line',
            data: {
                labels: ['2025', '2026', '2027', '2028', '2029', '2030', '2031', '2032', '2033', '2034'],
                datasets: [{
                    label: 'Base Case',
                    data: [200, 400, 600, 800, 1000, 1200, 1100, 900, 700, 500],
                    borderColor: '#0a6b5e',
                    backgroundColor: 'rgba(10, 107, 94, 0.1)',
                    tension: 0.3,
                    borderWidth: 2
                }, {
                    label: 'Bull Case',
                    data: [250, 500, 800, 1200, 1600, 2000, 1900, 1600, 1200, 800],
                    borderColor: '#28a745',
                    backgroundColor: 'rgba(40, 167, 69, 0.1)',
                    tension: 0.3,
                    borderWidth: 2
                }, {
                    label: 'Conservative',
                    data: [150, 300, 400, 500, 600, 800, 750, 600, 450, 300],
                    borderColor: '#6c757d',
                    backgroundColor: 'rgba(108, 117, 125, 0.1)',
                    tension: 0.3,
                    borderWidth: 2
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'Global Sales Projections ($ millions)',
                        font: {
                            size: 16
                        }
                    },
                    legend: {
                        display: true,
                        position: 'top'
                    },
                    tooltip: {
                        mode: 'index',
                        intersect: false
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        title: {
                            display: true,
                            text: 'Sales ($ millions)'
                        }
                    },
                    x: {
                        title: {
                            display: true,
                            text: 'Year'
                        }
                    }
                }
            }
        });
    }

    // ==========================================
    // MARKET SHARE CHART
    // ==========================================
    const marketCtx = document.getElementById('marketShareChart');
    if (marketCtx) {
        new Chart(marketCtx.getContext('2d'), {
            type: 'doughnut',
            data: {
                labels: ['T-DXd (Enhertu)', 'T-DM1 (Kadcyla)', 'DV (RC48)', 'Trodelvy', 'Others/Chemo'],
                datasets: [{
                    data: [45, 15, 25, 10, 5],
                    backgroundColor: [
                        '#dc3545',
                        '#ffc107',
                        '#0a6b5e',
                        '#17a2b8',
                        '#6c757d'
                    ],
                    borderWidth: 2,
                    borderColor: '#fff'
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'Projected 2028 HER2+ ADC Market Share',
                        font: {
                            size: 16
                        }
                    },
                    legend: {
                        display: true,
                        position: 'bottom'
                    },
                    tooltip: {
                        callbacks: {
                            label: function(context) {
                                return context.label + ': ' + context.parsed + '%';
                            }
                        }
                    }
                }
            }
        });
    }

    // ==========================================
    // RISK ASSESSMENT RADAR CHART
    // ==========================================
    const riskCtx = document.getElementById('riskRadarChart');
    if (riskCtx) {
        new Chart(riskCtx.getContext('2d'), {
            type: 'radar',
            data: {
                labels: ['Clinical', 'Regulatory', 'Commercial', 'Manufacturing', 'IP', 'Financial', 'Team'],
                datasets: [{
                    label: 'Disitamab Vedotin Risk Profile',
                    data: [2, 3, 3, 2, 2, 2, 2],
                    backgroundColor: 'rgba(10, 107, 94, 0.2)',
                    borderColor: '#0a6b5e',
                    pointBackgroundColor: '#0a6b5e',
                    pointBorderColor: '#fff',
                    pointHoverBackgroundColor: '#fff',
                    pointHoverBorderColor: '#0a6b5e',
                    borderWidth: 2
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                scales: {
                    r: {
                        beginAtZero: true,
                        max: 5,
                        ticks: {
                            stepSize: 1
                        },
                        pointLabels: {
                            font: {
                                size: 12
                            }
                        }
                    }
                },
                plugins: {
                    title: {
                        display: true,
                        text: 'Risk Assessment Profile (1=Low, 5=High)',
                        font: {
                            size: 16
                        }
                    },
                    legend: {
                        display: false
                    }
                }
            }
        });
    }

    // ==========================================
    // EFFICACY COMPARISON CHART
    // ==========================================
    const efficacyCtx = document.getElementById('efficacyComparisonChart');
    if (efficacyCtx) {
        new Chart(efficacyCtx.getContext('2d'), {
            type: 'bar',
            data: {
                labels: ['ORR HER2+', 'ORR HER2-low', 'CBR HER2+', 'CBR HER2-low'],
                datasets: [{
                    label: 'Disitamab Vedotin',
                    data: [42.9, 33.3, 65, 50],
                    backgroundColor: '#0a6b5e'
                }, {
                    label: 'T-DXd',
                    data: [79, 52, 85, 65],
                    backgroundColor: '#dc3545'
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'Response Rate Comparison (%)'
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        max: 100,
                        title: {
                            display: true,
                            text: 'Response Rate (%)'
                        }
                    }
                }
            }
        });
    }

    // ==========================================
    // PATIENT POPULATION CHART
    // ==========================================
    const populationCtx = document.getElementById('populationChart');
    if (populationCtx) {
        new Chart(populationCtx.getContext('2d'), {
            type: 'pie',
            data: {
                labels: ['HER2+ (15-20%)', 'HER2-low (45-50%)', 'HER2-negative (30-40%)'],
                datasets: [{
                    data: [17.5, 47.5, 35],
                    backgroundColor: [
                        '#0a6b5e',
                        '#28a745',
                        '#6c757d'
                    ],
                    borderWidth: 2,
                    borderColor: '#fff'
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: true,
                plugins: {
                    title: {
                        display: true,
                        text: 'Breast Cancer HER2 Expression Distribution',
                        font: {
                            size: 16
                        }
                    },
                    legend: {
                        display: true,
                        position: 'bottom'
                    }
                }
            }
        });
    }

    // ==========================================
    // SMOOTH SCROLLING
    // ==========================================
    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener('click', function (e) {
            e.preventDefault();
            const target = document.querySelector(this.getAttribute('href'));
            if (target) {
                target.scrollIntoView({
                    behavior: 'smooth',
                    block: 'start'
                });
            }
        });
    });

    // ==========================================
    // PRINT FUNCTIONALITY
    // ==========================================
    window.printReport = function() {
        window.print();
    };

    // ==========================================
    // EXPORT TO PDF BUTTON (placeholder)
    // ==========================================
    window.exportToPDF = function() {
        alert('PDF export would be implemented with a library like jsPDF or server-side generation');
    };

});

   document.addEventListener('DOMContentLoaded', function() {
            lucide.createIcons();
        });
    </script>
</body>
</html>